MCID: CHL028
MIFTS: 60

Childhood Type Dermatomyositis

Categories: Blood diseases, Bone diseases, Muscle diseases, Nephrological diseases, Neuronal diseases, Rare diseases, Respiratory diseases, Skin diseases

Aliases & Classifications for Childhood Type Dermatomyositis

MalaCards integrated aliases for Childhood Type Dermatomyositis:

Name: Childhood Type Dermatomyositis 12 15
Juvenile Dermatomyositis 12 74 52 58 17 71 32
Juvenile Dm 52 58
Dermatomyositis, Childhood Type 71
Childhood Dermatomyositis 12

Characteristics:

Orphanet epidemiological data:

58
juvenile dermatomyositis
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Worldwide); Age of onset: Adolescent,Childhood,Infancy; Age of death: normal life expectancy;

Classifications:

Orphanet: 58  
Rare neurological diseases
Rare renal diseases
Rare respiratory diseases
Rare systemic and rhumatological diseases
Rare skin diseases


Summaries for Childhood Type Dermatomyositis

NIH Rare Diseases : 52 Juvenile dermatomyositis has some similarities to adult dermatomyositis and polymyositis . It typically affects children ages 2 to 15 years, with symptoms that include weakness of the muscles close to the trunk of the body, inflammation, edema , muscle pain, fatigue, skin rashes, abdominal pain, fever, and contractures . Children with juvenile dermatomyositis may have difficulty swallowing and breathing, and the heart may also be affected. About 20 to 30 percent of children with juvenile dermatomyositis develop calcium deposits in the soft tissue . Affected children may not show higher than normal levels of the muscle enzyme creatine kinase in their blood but have higher than normal levels of other muscle enzymes. Treatment is aimed at addressing the individual symptoms of each patient. This may involve a combination of medications, physical therapy and supplements.

MalaCards based summary : Childhood Type Dermatomyositis, also known as juvenile dermatomyositis, is related to interstitial lung disease and enthesopathy. An important gene associated with Childhood Type Dermatomyositis is CCR6 (C-C Motif Chemokine Receptor 6), and among its related pathways/superpathways are Akt Signaling and PAK Pathway. The drugs Abatacept and Vaccines have been mentioned in the context of this disorder. Affiliated tissues include skeletal muscle, skin and bone, and related phenotypes are muscle weakness and fatigue

Wikipedia : 74 Juvenile dermatomyositis (JDM) is an idiopathic inflammatory myopathy (IMM) of presumed autoimmune... more...

Related Diseases for Childhood Type Dermatomyositis

Diseases related to Childhood Type Dermatomyositis via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 420, show less)
# Related Disease Score Top Affiliating Genes
1 interstitial lung disease 31.1 TRIM21 TNF MORC3 IFIH1
2 enthesopathy 30.8 TNFRSF1B TNF CCR6
3 pustulosis of palm and sole 30.7 TNFRSF1B TNF CCR6
4 rheumatic disease 30.5 TRIM21 TNFRSF1B TNF ICOSLG CCR6
5 macrophage activation syndrome 30.5 TNFRSF1B TNF
6 autoimmune vasculitis 30.5 TNF CD4 CCR6
7 calcinosis 30.3 TNF PIK3C2A HLA-DQA1
8 autoimmune gastritis 30.2 TNF CD4 CCR6
9 mixed connective tissue disease 30.1 TNF SNRNP70 HLA-DQA1
10 cellulitis 30.1 TNF ICOSLG CD4 CCR6
11 skin disease 30.1 TNFRSF1B TNF MX1 ICOSLG CXCR3 CD4
12 herpes zoster 29.9 TNFRSF1B TNF ICOSLG CD4
13 mumps 29.9 TNFRSF1B TNF MX1
14 celiac disease 1 29.8 TNF ICOSLG HLA-DQA1 CD4 CCR6
15 bacterial infectious disease 29.8 TNF MX1 ICOSLG CD4 CCR6
16 uveitis 29.8 TNFRSF1B TNF CXCR5 CXCR3
17 chickenpox 29.8 TNFRSF1B TNF ICOSLG CD4 CCR6
18 lupus erythematosus 29.8 TRIM21 TNFRSF1B TNF SNRNP70 MX1 HLA-DQA1
19 adult dermatomyositis 29.6 TRIM33 TRIM24 TNF MORC3 IFIH1 DMBX1
20 psoriasis 29.6 TNFRSF1B TNF MIR10A IFIH1 CXCR3 CD4
21 dermatitis, atopic 29.6 TNF ICOSLG CXCR3 CD4 CCR6
22 central nervous system disease 29.5 TNF MIR10A ICOSLG CXCR3 CD4 CCR6
23 nervous system disease 29.5 TNF MIR10A ICOSLG CXCR3 CD4 CCR6
24 juvenile rheumatoid arthritis 29.5 TNFRSF1B TNF HLA-DQA1
25 systemic scleroderma 29.3 TRIM21 TNF SNRNP70 ICOSLG EXOSC10 CD4
26 primary biliary cirrhosis 29.3 TNF HLA-DQA1 CXCR5 CXCR3 CD4
27 myositis 29.0 TRIM33 TRIM21 TNF PIK3C2A IFIH1 ICOSLG
28 connective tissue disease 29.0 TNFRSF1B TNF SNRNP70 ICOSLG HLA-DQA1 CD4
29 exanthem 28.8 TRIM21 TNFRSF1B TNF PIK3C2A IFIH1 ICOSLG
30 autoimmune disease 28.6 TRIM21 TNFRSF1B TNF IFIH1 ICOSLG HLA-DQA1
31 rheumatoid arthritis 28.4 TNFRSF1B TNF HLA-DQA1 CXCR5 CXCR3 CD4
32 systemic lupus erythematosus 28.4 TRIM21 TNFRSF1B TNF SNRNP70 MX1 IFIH1
33 muscular disease 28.2 TRIM33 TRIM21 TNFRSF1B TNF SNRNP70 PIK3C2A
34 dermatomyositis 10.6
35 juvenile overlap myositis 10.5
36 lung disease 10.5
37 mikulicz disease 10.5 ICOSLG CD4 CCR6
38 subacute cutaneous lupus erythematosus 10.5 TRIM21 TNF
39 dacryoadenitis 10.4 ICOSLG CD4 CCR6
40 autoimmune glomerulonephritis 10.4 ICOSLG CD4 CCR6
41 facial hemiatrophy 10.4 SNRNP70 EXOSC10
42 myelitis 10.4 TNF ICOSLG CCR6
43 nut allergy 10.4 ICOSLG CD4 CCR6
44 monoclonal gammopathy of uncertain significance 10.4 TNF ICOSLG CCR6
45 thrombocytopenia due to platelet alloimmunization 10.4 ICOSLG CD4 CCR6
46 igg4-related disease 10.4 ICOSLG CD4 CCR6
47 autoimmune disease of skin and connective tissue 10.4 ICOSLG CD4 CCR6
48 primary thrombocytopenia 10.4 ICOSLG CD4 CCR6
49 autoimmune disease of blood 10.4 ICOSLG CD4 CCR6
50 immunoglobulin alpha deficiency 10.4 ICOSLG CD4 CCR6
51 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 10.4 ICOSLG CD4 CCR6
52 bullous skin disease 10.4 ICOSLG CD4 CCR6
53 thymus gland disease 10.4 ICOSLG CD4 CCR6
54 diffuse scleroderma 10.4 TRIM21 SNRNP70 EXOSC10
55 thymus cancer 10.4 ICOSLG CD4 CCR6
56 pneumonic tularemia 10.4 TNF CD4 CCR6
57 blastomycosis 10.4 TNF CD4 CCR6
58 dyskinesia of esophagus 10.4 TRIM21 SNRNP70 EXOSC10
59 thrombocytopenic purpura, autoimmune 10.4 ICOSLG CD4 CCR6
60 diabetes mellitus, insulin-dependent, 23 10.4 TNF CD4
61 b cell deficiency 10.4 ICOSLG CD4 CCR6
62 combined t cell and b cell immunodeficiency 10.4 ICOSLG CD4 CCR6
63 dysphagia 10.4
64 neuromuscular junction disease 10.4 ICOSLG CD4 CCR6
65 rheumatoid arthritis interstitial lung disease 10.4 TNFRSF1B TNF
66 autoimmune disease of peripheral nervous system 10.4 TNF ICOSLG CD4
67 juvenile ankylosing spondylitis 10.4 TNFRSF1B TNF
68 suppurative lymphadenitis 10.4 CD4 CCR6
69 blepharitis 10.4 TNF CD4 CCR6
70 lymphatic system cancer 10.4 ICOSLG CD4 CCR6
71 vaginitis 10.4 TNF CD4 CCR6
72 scleritis 10.4 TNFRSF1B TNF CCR6
73 gingival disease 10.4 TNF CD4 CCR6
74 cryptococcosis 10.4 TNF CD4 CCR6
75 cheilitis 10.4 TNF CD4 CCR6
76 keratoconjunctivitis sicca 10.4 TRIM21 CD4 CCR6
77 splenic disease 10.4 TNF CD4 CCR6
78 vaginal disease 10.4 TNF CD4 CCR6
79 middle ear disease 10.4 TNF CD4 CCR6
80 spongiotic dermatitis 10.4 CD4 CCR6
81 dysentery 10.4 TNF CD4 CCR6
82 anus disease 10.3 TNF CD4 CCR6
83 sarcoid meningitis 10.3 TNFRSF1B PIK3C2A
84 cranial nerve disease 10.3 ICOSLG CD4 CCR6
85 subacute sclerosing panencephalitis 10.3 TNF MX1 IFIH1
86 rectal disease 10.3 TNF CD4 CCR6
87 dry eye syndrome 10.3 TRIM21 TNF CCR6
88 meningoencephalitis 10.3 TNF CD4 CCR6
89 pyoderma 10.3 TNFRSF1B TNF CCR6
90 orbital plasma cell granuloma 10.3 TNFRSF1B PIK3C2A MORC3
91 beryllium disease 10.3 TNF HLA-DQA1
92 pustulosis palmaris et plantaris 10.3 TNF CXCR3 CCR6
93 vitiligo-associated multiple autoimmune disease susceptibility 1 10.3 ICOSLG CD4 CCR6
94 hydrops, lactic acidosis, and sideroblastic anemia 10.3
95 ankylosis 10.3 TNFRSF1B TNF CCR6
96 acute cystitis 10.3 TNF CD4 CCR6
97 mature b-cell neoplasm 10.3 ICOSLG CD4 CCR6
98 neonatal lupus erythematosus 10.3 TRIM21 HLA-DQA1
99 keratitis, hereditary 10.3 TNF CD4 CCR6
100 chediak-higashi syndrome 10.3 ICOSLG CD4 CCR6
101 arteries, anomalies of 10.3 TNF MIR10A ICOSLG CCR6
102 autoimmune disease of cardiovascular system 10.3 TNF ICOSLG CD4 CCR6
103 hantavirus hemorrhagic fever with renal syndrome 10.3 TNF MX1 CD4
104 telangiectasis 10.3 TRIM21 SNRNP70 EXOSC10 CCR6
105 intermediate uveitis 10.3 TNF CXCR3 CCR6
106 chronic conjunctivitis 10.3 TNF ICOSLG CD4 CCR6
107 acute proliferative glomerulonephritis 10.3 TNF ICOSLG CD4 CCR6
108 autoimmune disease of eyes, ear, nose and throat 10.3 TNF ICOSLG CD4 CCR6
109 viral pneumonia 10.3 TNF MX1 CD4
110 skin sarcoidosis 10.3 TNFRSF1B TNF CD4
111 mononeuropathy 10.3 TRIM21 TNFRSF1B TNF
112 spondylitis 10.3 TNFRSF1B TNF CCR6
113 lichen disease 10.3 TNF ICOSLG CD4 CCR6
114 pleural disease 10.3 TNF CD4 CCR6
115 limited scleroderma 10.3 TRIM21 SNRNP70 EXOSC10 CCR6
116 opportunistic bacterial infectious disease 10.3 TNFRSF1B TNF CD4
117 listeriosis 10.3 TNF ICOSLG CD4 CCR6
118 progressive multifocal leukoencephalopathy 10.3 TNF ICOSLG CD4 CCR6
119 nocardiosis 10.3 TNFRSF1B TNF CD4
120 conjunctival disease 10.3 TNF ICOSLG CD4 CCR6
121 neurosarcoidosis 10.3 TNFRSF1B TNF CD4
122 cervix disease 10.3 MIR10A ICOSLG CD4 CCR6
123 coccidiosis 10.3 TNF ICOSLG CD4 CCR6
124 autoimmune disease of endocrine system 10.3 TNF ICOSLG CD4 CCR6
125 opportunistic mycosis 10.3 TNF ICOSLG CD4 CCR6
126 granulomatous dermatitis 10.3 TNFRSF1B TNF CD4
127 nasal cavity disease 10.3 TNF ICOSLG CD4 CCR6
128 paranasal sinus disease 10.3 TNF ICOSLG CD4 CCR6
129 spinal cord disease 10.3 TNF ICOSLG CD4 CCR6
130 common cold 10.3 TNF ICOSLG CD4 CCR6
131 nose disease 10.3 TNF ICOSLG CD4 CCR6
132 respiratory allergy 10.3 TNF ICOSLG CD4 CCR6
133 commensal bacterial infectious disease 10.3 TNF ICOSLG CD4 CCR6
134 hypotrichosis 1 10.3 TNF ICOSLG CD4 CCR6
135 hypotrichosis 10.3 TNF ICOSLG CD4 CCR6
136 parasitic helminthiasis infectious disease 10.3 TNF ICOSLG CD4 CCR6
137 uveoparotid fever 10.3 TNFRSF1B TNF CD4
138 good syndrome 10.3 TNFRSF1B TNF CD4
139 salmonellosis 10.3 TNF CD4 CCR6
140 mononeuritis of upper limb and mononeuritis multiplex 10.3 TRIM21 TNFRSF1B CD4
141 mononeuritis multiplex 10.3 TRIM21 TNFRSF1B CD4
142 miliary tuberculosis 10.3 TNFRSF1B TNF CD4
143 herpangina 10.3 TNF IFIH1 CD4 CCR6
144 chorioretinitis 10.3 TNFRSF1B TNF CD4
145 iridocyclitis 10.3 TNFRSF1B TNF CD4
146 bacterial pneumonia 10.3 TNF ICOSLG CD4 CCR6
147 hair disease 10.3 TNF ICOSLG CD4 CCR6
148 blood coagulation disease 10.3 TNF ICOSLG CD4 CCR6
149 mouth disease 10.3 MX1 IFIH1 ICOSLG CCR6
150 lymphatic system disease 10.3 TNF ICOSLG CD4 CCR6
151 nasopharyngitis 10.3 TNFRSF1B TNF CD4
152 pharyngitis 10.3 TNFRSF1B TNF CD4
153 parasitic protozoa infectious disease 10.3 TNF ICOSLG CD4 CCR6
154 testicular disease 10.3 TNF CD4 CCR6
155 bronchial disease 10.3 TNF ICOSLG CD4 CCR6
156 necrobiosis lipoidica 10.3 TNFRSF1B TNF
157 bile duct disease 10.3 TNF ICOSLG CD4 CCR6
158 cholangitis, primary sclerosing 10.3 TNF ICOSLG CD4 CCR6
159 muscular dystrophy 10.3
160 spondyloarthropathy 1 10.3 TNFRSF1B TNF ICOSLG CCR6
161 pyomyositis 10.3 PIK3C2A CD4
162 optic nerve disease 10.3 TNF ICOSLG CD4 CCR6
163 dengue disease 10.3 TNF PIK3C2A ICOSLG CCR6
164 optic papillitis 10.3 TNFRSF1B CD4
165 blood platelet disease 10.2 TNF ICOSLG CD4 CCR6
166 crimean-congo hemorrhagic fever 10.2 TNF PIK3C2A MX1
167 upper respiratory tract disease 10.2 TNF ICOSLG CD4 CCR6
168 pulmonary sarcoidosis 10.2 TNF CXCR3 CCR6
169 leukocyte disease 10.2 TNF ICOSLG CD4 CCR6
170 respiratory failure 10.2
171 juvenile polymyositis 10.2
172 endocardium disease 10.2 TNF PIK3C2A CD4
173 autosomal genetic disease 10.2 TNF ICOSLG CD4 CCR6
174 glucose metabolism disease 10.2 TNF ICOSLG CD4 CCR6
175 demyelinating disease 10.2 TNF ICOSLG CD4 CCR6
176 corneal disease 10.2 TNF CD4 CCR6
177 granulomatous hepatitis 10.2 TNFRSF1B CD4
178 viral encephalitis 10.2 TNF MX1 CD4 CCR6
179 peripheral nervous system disease 10.2 TNF ICOSLG CD4 CCR6
180 acquired metabolic disease 10.2 TNF ICOSLG CD4 CCR6
181 allergic hypersensitivity disease 10.2 TNF ICOSLG CD4 CCR6
182 scleral disease 10.2 TNFRSF1B TNF CD4 CCR6
183 iritis 10.2 TNFRSF1B TNF CD4 CCR6
184 central nervous system vasculitis 10.2 TNFRSF1B TNF CD4 CCR6
185 primary systemic mycosis 10.2 TNFRSF1B TNF CD4 CCR6
186 pneumocystosis 10.2 TNFRSF1B TNF CD4 CCR6
187 panuveitis 10.2 TNFRSF1B TNF CD4 CCR6
188 severe cutaneous adverse reaction 10.2 TNFRSF1B TNF CD4
189 gastrointestinal tuberculosis 10.2 TNF CD4
190 temporal arteritis 10.2 TNFRSF1B TNF CD4 CCR6
191 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.2
192 x-linked recessive disease 10.2 ICOSLG CD4 CCR6
193 respiratory system disease 10.2 MIR10A ICOSLG CD4 CCR6
194 sezary's disease 10.2 TNFRSF1B CD4 CCR6
195 guillain-barre syndrome 10.2 TNFRSF1B TNF HLA-DQA1
196 combined thymoma 10.1 TNF CD4
197 hypertrichosis 10.1
198 myocarditis 10.1
199 lymphoma, mucosa-associated lymphoid type 10.1 CXCR5 CXCR3 CD4 CCR6
200 oligoarticular juvenile idiopathic arthritis 10.1 TNF HLA-DQA1 CXCR3
201 allergic contact dermatitis 10.1 TNF CXCR3 CD4
202 contact dermatitis 10.1 TNF CXCR3 CD4
203 chronic mucocutaneous candidiasis 10.1 TNF CD4 CCRL2 CCR6
204 sialadenitis 10.1 TRIM21 TNF ICOSLG CD4 CCR6
205 lacrimal apparatus disease 10.1 TRIM21 TNF ICOSLG CD4 CCR6
206 autoimmune disease of urogenital tract 10.1 TRIM21 TNF ICOSLG CD4 CCR6
207 lymphoid interstitial pneumonia 10.1 TRIM21 TNFRSF1B TNF CD4
208 lymph node disease 10.1 TRIM21 TNF ICOSLG CD4 CCR6
209 salivary gland disease 10.1 TRIM21 TNF ICOSLG CD4 CCR6
210 neuromuscular disease 10.1 TNF ICOSLG CD4 CCR6
211 lichen planus 10.1 TNF MX1 CXCR3
212 immune system disease 10.1 TRIM21 TNF ICOSLG CD4 CCR6
213 endocarditis 10.1 TNFRSF1B TNF PIK3C2A
214 leprosy 3 10.1 TNF HLA-DQA1 CD4 CCR6
215 hypertriglyceridemia, familial 10.1
216 proteasome-associated autoinflammatory syndrome 1 10.1
217 pneumothorax 10.1
218 dermatitis 10.1
219 alopecia 10.1
220 raynaud phenomenon 10.1
221 systemic autoimmune disease 10.1
222 autoimmune peripheral neuropathy 10.1 ICOSLG CD4
223 hypersensitivity reaction type iv disease 10.1 TNFRSF1B TNF ICOSLG CD4 CCR6
224 uveal disease 10.1 TNFRSF1B TNF ICOSLG CD4 CCR6
225 primary bacterial infectious disease 10.1 TNFRSF1B TNF ICOSLG CD4 CCR6
226 granulomatosis with polyangiitis 10.1 TNFRSF1B TNF ICOSLG CD4 CCR6
227 cutaneous lupus erythematosus 10.1 TRIM21 TNF MX1 CXCR3
228 bone inflammation disease 10.1 TNFRSF1B TNF ICOSLG CD4 CCR6
229 crohn's disease 10.1 TNFRSF1B TNF ICOSLG CD4 CCR6
230 wissler's syndrome 10.0 TNFRSF1B CD4
231 behcet syndrome 10.0 TNFRSF1B TNF ICOSLG CD4 CCR6
232 rubella 10.0 TNFRSF1B TNF HLA-DQA1
233 acquired immunodeficiency syndrome 10.0 TNFRSF1B TNF CXCR5 CD4 CCR6
234 vasculitis 10.0
235 polymyositis 10.0
236 optic neuritis 10.0 TNF HLA-DQA1 CXCR3
237 muscular dystrophy, duchenne type 10.0
238 thrombocytopenia 10.0
239 keratosis 10.0
240 pericarditis 10.0
241 idiopathic interstitial pneumonia 10.0
242 acute pancreatitis 10.0
243 pulmonary fibrosis 10.0
244 lymphopenia 10.0
245 cataract 10.0
246 juvenile idiopathic inflammatory myopathy 10.0
247 lymphadenitis 10.0 TNF ICOSLG CXCR3 CD4 CCR6
248 autoimmune disease of central nervous system 10.0 TNF ICOSLG CXCR3 CD4 CCR6
249 muscle tissue disease 10.0 TNF PIK3C2A MORC3 IFIH1 ICOSLG CCR6
250 alopecia areata 10.0 TNF ICOSLG HLA-DQA1 CXCR3
251 autoimmune disease of gastrointestinal tract 10.0 TNF ICOSLG HLA-DQA1 CD4 CCR6
252 pulmonary disease, chronic obstructive 10.0 TNF ICOSLG CXCR3 CD4 CCR6
253 pulmonary fibrosis, idiopathic 10.0 TNF ICOSLG CXCR3 CD4 CCR6
254 coronary artery anomaly 9.9 TNFRSF1B TNF PIK3C2A CD4
255 extrinsic cardiomyopathy 9.9 TNF PIK3C2A MIR10A ICOSLG CD4 CCR6
256 nail disease 9.9 TNFRSF1B TNF CD4 CCRL2 CCR6
257 acanthosis nigricans 9.9
258 pneumothorax, primary spontaneous 9.9
259 body mass index quantitative trait locus 1 9.9
260 graft-versus-host disease 9.9
261 nephrotic syndrome 9.9
262 polyneuropathy 9.9
263 capillary leak syndrome 9.9
264 vascular disease 9.9
265 lipid metabolism disorder 9.9
266 purpura 9.9
267 pneumonia 9.9
268 hemolytic anemia 9.9
269 thyroiditis 9.9
270 toxoplasmosis 9.9
271 berardinelli-seip congenital lipodystrophy 9.9
272 systemic onset juvenile idiopathic arthritis 9.9
273 avascular necrosis 9.9
274 histoplasmosis 9.9 TNFRSF1B TNF HLA-DQA1 CD4 CCR6
275 myopathy 9.9
276 lymphoma, non-hodgkin, familial 9.9 TNFRSF1B TNF ICOSLG CXCR5 CD4 CCR6
277 diabetes mellitus, insulin-dependent 9.8 TNF IFIH1 ICOSLG HLA-DQA1 CD4 CCR6
278 human immunodeficiency virus infectious disease 9.8 TNF MX1 ICOSLG CXCR3 CD4 CCR6
279 collagen disease 9.8 TRIM21 TNF SNRNP70 ICOSLG EXOSC10 CD4
280 leukemia, chronic lymphocytic 9.8 TNF ICOSLG CXCR5 CXCR3 CD4 CCR6
281 sarcoidosis 1 9.8 TNFRSF1B TNF ICOSLG CXCR3 CD4 CCR6
282 mycobacterium tuberculosis 1 9.8 TNFRSF1B TNF ICOSLG CXCR3 CD4 CCR6
283 pfeiffer syndrome 9.8
284 gastroesophageal reflux 9.8
285 hashimoto thyroiditis 9.8
286 inclusion body myositis 9.8
287 kaposi sarcoma 9.8
288 nevus, epidermal 9.8
289 osteoporosis 9.8
290 teratoma, ovarian 9.8
291 pernicious anemia 9.8
292 pulmonary hemosiderosis 9.8
293 scleroderma, familial progressive 9.8
294 digeorge syndrome 9.8
295 triiodothyronine receptor auxiliary protein 9.8
296 cryptorchidism, unilateral or bilateral 9.8
297 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 9.8
298 immune deficiency disease 9.8
299 premature ovarian failure 1 9.8
300 gallbladder disease 1 9.8
301 malignant atrophic papulosis 9.8
302 brittle bone disorder 9.8
303 resting heart rate, variation in 9.8
304 kala-azar 1 9.8
305 lipodystrophy, partial, acquired 9.8
306 diabetes mellitus, insulin-resistant, with acanthosis nigricans 9.8
307 bone mineral density quantitative trait locus 8 9.8
308 fatty liver disease, nonalcoholic 1 9.8
309 bone mineral density quantitative trait locus 15 9.8
310 lipedema 9.8
311 complement component 4a deficiency 9.8
312 encephalopathy, progressive, early-onset, with episodic rhabdomyolysis 9.8
313 gastrointestinal ulceration, recurrent, with dysfunctional platelets 9.8
314 deficiency anemia 9.8
315 hemophagocytic lymphohistiocytosis 9.8
316 cryptogenic organizing pneumonia 9.8
317 inflammatory bowel disease 9.8
318 lymphoma 9.8
319 diffuse alopecia areata 9.8
320 colitis 9.8
321 crest syndrome 9.8
322 thrombosis 9.8
323 oligoasthenoteratozoospermia 9.8
324 bone resorption disease 9.8
325 acquired generalized lipodystrophy 9.8
326 non-alcoholic steatohepatitis 9.8
327 osteonecrosis 9.8
328 neuroretinitis 9.8
329 osteomyelitis 9.8
330 glucose intolerance 9.8
331 rickets 9.8
332 thrombotic thrombocytopenic purpura 9.8
333 chorioretinal scar 9.8
334 t cell deficiency 9.8
335 erysipelas 9.8
336 esophagitis 9.8
337 hemosiderosis 9.8
338 spinal muscular atrophy 9.8
339 dilated cardiomyopathy 9.8
340 cholestasis 9.8
341 hypothyroidism 9.8
342 candidiasis 9.8
343 urticaria 9.8
344 cholecystitis 9.8
345 hyperinsulinism 9.8
346 hepatitis b 9.8
347 autoimmune hepatitis 9.8
348 hepatitis 9.8
349 iron metabolism disease 9.8
350 synovitis 9.8
351 bronchiolitis obliterans 9.8
352 acalculous cholecystitis 9.8
353 glomerulonephritis 9.8
354 bronchiolitis 9.8
355 iga glomerulonephritis 9.8
356 gingivitis 9.8
357 lipomatosis 9.8
358 teratoma 9.8
359 superior mesenteric artery syndrome 9.8
360 retinitis 9.8
361 gastritis 9.8
362 hyperglycemia 9.8
363 angiokeratoma 9.8
364 pancreatitis 9.8
365 chronic polyneuropathy 9.8
366 mature teratoma 9.8
367 ovarian germ cell teratoma 9.8
368 congestive heart failure 9.8
369 myositis ossificans 9.8
370 cerebrovascular disease 9.8
371 b-cell lymphoma 9.8
372 muscular atrophy 9.8
373 scabies 9.8
374 influenza 9.8
375 localized scleroderma 9.8
376 arthritis 9.8
377 ulcerative colitis 9.8
378 neuromyelitis optica 9.8
379 leishmaniasis 9.8
380 amyloidosis 9.8
381 bronchiectasis 9.8
382 polyarteritis nodosa 9.8
383 hypereosinophilic syndrome 9.8
384 hypertrophic cardiomyopathy 9.8
385 sickle cell disease 9.8
386 anca-associated vasculitis 9.8
387 atypical werner syndrome 9.8
388 chronic graft versus host disease 9.8
389 cutaneous polyarteritis nodosa 9.8
390 erythrokeratoderma ''en cocardes'' 9.8
391 homologous wasting disease 9.8
392 leukoplakia 9.8
393 splenomegaly 9.8
394 hypotonia 9.8
395 rare systemic disease 9.8
396 progeroid syndrome 9.8
397 cerebrofacial arteriovenous metameric syndrome 9.8
398 secondary hemophagocytic lymphohistiocytosis 9.8
399 pik3ca-related overgrowth syndrome 9.8
400 pediatric systemic lupus erythematosus 9.8
401 thrombotic microangiopathy 9.8
402 acquired lipodystrophy 9.8
403 acroosteolysis 9.7
404 fibrodysplasia ossificans progressiva 9.7
405 papilloma of choroid plexus 9.7
406 aspiration pneumonia 9.7
407 basal ganglia calcification 9.7
408 myoglobinuria 9.7
409 neutropenia 9.7
410 squamous cell papilloma 9.7
411 panniculitis 9.7
412 intestinal perforation 9.7
413 papilloma 9.7
414 gastrointestinal system disease 9.7
415 cytokine deficiency 9.7
416 autoimmune disease of musculoskeletal system 9.7 TRIM21 TNFRSF1B TNF SNRNP70 ICOSLG CD4
417 pericardium disease 9.7 TRIM21 TNFRSF1B TNF SNRNP70 PIK3C2A CD4
418 viral infectious disease 9.7 TNF MX1 IFIH1 ICOSLG CXCR3 CD4
419 stomatitis 9.7 TNF MX1 CD4
420 multiple sclerosis 9.2 TNFRSF1B TNF MX1 HLA-DQA1 CXCR5 CXCR3

Graphical network of the top 20 diseases related to Childhood Type Dermatomyositis:



Diseases related to Childhood Type Dermatomyositis

Symptoms & Phenotypes for Childhood Type Dermatomyositis

Human phenotypes related to Childhood Type Dermatomyositis:

58 31 (showing 47, show less)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 muscle weakness 58 31 hallmark (90%) Very frequent (99-80%) HP:0001324
2 fatigue 58 31 hallmark (90%) Very frequent (99-80%) HP:0012378
3 dry skin 58 31 hallmark (90%) Very frequent (99-80%) HP:0000958
4 skin rash 58 31 hallmark (90%) Very frequent (99-80%) HP:0000988
5 erythema 58 31 hallmark (90%) Very frequent (99-80%) HP:0010783
6 telangiectasia of the skin 58 31 hallmark (90%) Very frequent (99-80%) HP:0100585
7 autoimmunity 58 31 hallmark (90%) Very frequent (99-80%) HP:0002960
8 myalgia 58 31 hallmark (90%) Very frequent (99-80%) HP:0003326
9 mucosal telangiectasiae 58 31 hallmark (90%) Very frequent (99-80%) HP:0100579
10 myositis 58 31 hallmark (90%) Very frequent (99-80%) HP:0100614
11 palpebral edema 58 31 hallmark (90%) Very frequent (99-80%) HP:0100540
12 elevated c-reactive protein level 58 31 hallmark (90%) Very frequent (99-80%) HP:0011227
13 elevated erythrocyte sedimentation rate 58 31 hallmark (90%) Very frequent (99-80%) HP:0003565
14 calcinosis 58 31 hallmark (90%) Very frequent (99-80%) HP:0003761
15 elevated serum creatine kinase 31 hallmark (90%) HP:0003236
16 constipation 58 31 frequent (33%) Frequent (79-30%) HP:0002019
17 muscular hypotonia 58 31 frequent (33%) Frequent (79-30%) HP:0001252
18 arthritis 58 31 frequent (33%) Frequent (79-30%) HP:0001369
19 alopecia 58 31 frequent (33%) Frequent (79-30%) HP:0001596
20 fever 58 31 frequent (33%) Frequent (79-30%) HP:0001945
21 arthralgia 58 31 frequent (33%) Frequent (79-30%) HP:0002829
22 pruritus 58 31 frequent (33%) Frequent (79-30%) HP:0000989
23 cutaneous photosensitivity 58 31 frequent (33%) Frequent (79-30%) HP:0000992
24 skin ulcer 58 31 frequent (33%) Frequent (79-30%) HP:0200042
25 restrictive ventilatory defect 58 31 frequent (33%) Frequent (79-30%) HP:0002091
26 vasculitis 58 31 frequent (33%) Frequent (79-30%) HP:0002633
27 poikiloderma 58 31 frequent (33%) Frequent (79-30%) HP:0001029
28 muscle spasm 31 frequent (33%) HP:0003394
29 dysarthria 58 31 occasional (7.5%) Occasional (29-5%) HP:0001260
30 dysphonia 58 31 occasional (7.5%) Occasional (29-5%) HP:0001618
31 dysphagia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002015
32 pulmonary fibrosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0002206
33 dyspnea 58 31 occasional (7.5%) Occasional (29-5%) HP:0002094
34 emg abnormality 58 31 occasional (7.5%) Occasional (29-5%) HP:0003457
35 arrhythmia 58 31 occasional (7.5%) Occasional (29-5%) HP:0011675
36 angina pectoris 58 31 occasional (7.5%) Occasional (29-5%) HP:0001681
37 abdominal pain 58 31 occasional (7.5%) Occasional (29-5%) HP:0002027
38 weight loss 58 31 occasional (7.5%) Occasional (29-5%) HP:0001824
39 limitation of joint mobility 58 31 occasional (7.5%) Occasional (29-5%) HP:0001376
40 pericarditis 58 31 occasional (7.5%) Occasional (29-5%) HP:0001701
41 gastrointestinal hemorrhage 58 31 occasional (7.5%) Occasional (29-5%) HP:0002239
42 cough 58 31 occasional (7.5%) Occasional (29-5%) HP:0012735
43 cardiomyopathy 58 31 occasional (7.5%) Occasional (29-5%) HP:0001638
44 bundle branch block 58 31 occasional (7.5%) Occasional (29-5%) HP:0011710
45 hoarse voice 58 31 occasional (7.5%) Occasional (29-5%) HP:0001609
46 elevated serum creatine phosphokinase 58 Very frequent (99-80%)
47 muscle cramps 58 Frequent (79-30%)

MGI Mouse Phenotypes related to Childhood Type Dermatomyositis:

45 (showing 2, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.7 CCR6 CCRL2 CD4 CXCR3 CXCR5 HLA-DQA1
2 immune system MP:0005387 9.4 CCR6 CCRL2 CD4 CXCR3 CXCR5 HLA-DQA1

Drugs & Therapeutics for Childhood Type Dermatomyositis

Drugs for Childhood Type Dermatomyositis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 60, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Abatacept Approved Phase 4 332348-12-6 10237
2 Vaccines Phase 4
3 Immunologic Factors Phase 4
4 Antirheumatic Agents Phase 4
5 Immunosuppressive Agents Phase 4
6 Melanocyte-Stimulating Hormones Phase 4
7 Adrenocorticotropic Hormone Phase 4
8 beta-endorphin Phase 4
9
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
10
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
11
Alendronate Approved Phase 2, Phase 3 121268-17-5, 66376-36-1 2088
12
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
13
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
14
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
15 Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
16
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
17
Methotrexate Approved Phase 2, Phase 3 1959-05-2, 59-05-2 126941
18
leucovorin Approved Phase 2, Phase 3 58-05-9 6006 143
19
Prednisone Approved, Vet_approved Phase 2, Phase 3 53-03-2 5865
20
Etanercept Approved, Investigational Phase 2, Phase 3 185243-69-0
21
Folic acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
22
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
23 Cyclosporins Phase 3
24 Antifungal Agents Phase 3
25 Calcineurin Inhibitors Phase 3
26 Methylprednisolone Acetate Phase 3
27 glucocorticoids Phase 2, Phase 3
28 Folic Acid Antagonists Phase 2, Phase 3
29 Vitamin B9 Phase 2, Phase 3
30 Vitamin B Complex Phase 2, Phase 3
31 Dermatologic Agents Phase 2, Phase 3
32 Folate Phase 2, Phase 3
33 Hormone Antagonists Phase 2, Phase 3
34 Gastrointestinal Agents Phase 2, Phase 3
35 Antineoplastic Agents, Hormonal Phase 2, Phase 3
36 Antimetabolites Phase 2, Phase 3
37 Anti-Inflammatory Agents Phase 2, Phase 3
38 Hormones Phase 2, Phase 3
39 Analgesics Phase 2, Phase 3
40 Analgesics, Non-Narcotic Phase 2, Phase 3
41 Anti-Inflammatory Agents, Non-Steroidal Phase 2, Phase 3
42
rituximab Approved Phase 2 174722-31-7 10201696
43
Calcium Approved, Nutraceutical Phase 2 7440-70-2 271
44 Antiemetics Phase 2
45 Neuroprotective Agents Phase 2
46 Autonomic Agents Phase 2
47 Pharmaceutical Solutions Phase 2
48 Antineoplastic Agents, Immunological Phase 2
49 Anti-Infective Agents Phase 2
50 Protective Agents Phase 2
51 Chelating Agents Phase 2
52 Antitubercular Agents Phase 2
53 Antioxidants Phase 2
54 Calcium, Dietary Phase 2
55 sodium thiosulfate Phase 2
56 Antidotes Phase 2
57 Anti-Bacterial Agents Phase 2
58
Creatine Approved, Investigational, Nutraceutical 57-00-1 586
59 Antibodies
60 Immunoglobulins

Interventional clinical trials:

(showing 27, show less)
# Name Status NCT ID Phase Drugs
1 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
2 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Completed NCT00815282 Phase 4
3 Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis Recruiting NCT02245841 Phase 4 H.P. Acthar Gel
4 Abatacept for the Treatment of Refractory Juvenile Dermatomyositis Recruiting NCT02594735 Phase 4 Abatacept
5 Five-year Single-blind, Phase III Effectiveness Randomised Actively Controlled Clinical Trial in New Onset Juvenile Dermatomyositis: Prednisone Versus Prednisone Plus Cyclosporine a Versus Prednisone Plus Methotrexate Unknown status NCT00323960 Phase 3 3 MPDN pulse + PDN;3 MPDN pulse + PDN + CSA;3 MPDN pulse + PDN + MTX
6 Double Blind Controlled Trial of Alendronate for the Treatment of Childhood and Adolescent Glucocorticoid-Associated Osteopenia and Osteoporosis Unknown status NCT00209469 Phase 2, Phase 3 alendronate sodium
7 Double-Blinded Controlled Trial of Alendronate for the Treatment of Childhood and Adolescent Glucocorticoid- Associated Osteopenia and Osteoporosis Completed NCT00277251 Phase 2, Phase 3 Alendronate
8 A Prospective, Randomised, Assessor-blind, Multicenter Study of Efficacy and Safety of Combined Treatment of Methotrexate + Glucocorticoids Versus Glucocorticoids Alone in Patients With Polymyositis and Dermatomyositis. Completed NCT00651040 Phase 3 Prednisone;Methotrexate
9 Toward Improved Understanding of Pathogenesis and Treatment of Childhood Onset Dermatomyositis Terminated NCT00035958 Phase 2, Phase 3 Prednisone;Methotrexate;Etanercept
10 Phase II Study of Prednisolone/Methylprednisolone Absorption in Children With Juvenile Dermatomyositis Completed NCT00004357 Phase 2 Methylprednisolone;Prednisolone
11 Novel Drug Delivery of Sodium Thiosulfate for Calcinosis Associated With Adult and Juvenile Dermatomyositis Completed NCT01572844 Phase 2 Sodium thiosulfate
12 Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis Completed NCT02043548 Phase 2 tocilizumab;placebo
13 Rituximab Therapy in Refractory Adult and Juvenile Idiopathic Inflammatory Myopathy (IIM) Completed NCT00106184 Phase 2 Rituximab;Placebo
14 An Open-label Study of Sodium Thiosulfate for Treatment of Calcinosis Associated With Juvenile and Adult Dermatomyositis Recruiting NCT03267277 Phase 2 Sodium Thiosulfate
15 Efficacy and Safety of Creatine Supplementation in Patients With Juvenile Systemic Lupus Erythematosus and Juvenile Dermatomyositis Unknown status NCT01217320
16 Studies on Tissues From Patients With Fibrous Dysplasia of Bone/McCune-Albright Syndrome and Other Disorders of Calcified Tissues Completed NCT00001973
17 Fatigue and Sleep in Children and Adolescents With Juvenile Idiopathic Arthritis: A Cross-Sectional Study Completed NCT03618680
18 The Effect of Creatine Supplementation on Muscle Function in Childhood Myositis Completed NCT02267005
19 Evaluation of Yellow Fever Vaccine in Patients With Rheumatic Diseases Under Low Immunosuppression Level and Residing in a Risk Area Completed NCT03430388
20 The CARRA Registry Completed NCT01697254
21 Steroid-Induced Osteoporosis in the Pediatric Population - Canadian Incidence Study (STOPP-CIS) Completed NCT01663129
22 Incidence and Prevalence of Juvenile Dermatomyositis in Alsace Between 2000 to 2015 Recruiting NCT03432455
23 Retrospective Descriptive Study of Juvenile Dermatomyositis in Alsace Recruiting NCT03433638
24 Studies of Natural History, Pathogenesis, and Outcomes in Autoimmune and Inflammatory Diseases Including Juvenile Dermatomyositis Recruiting NCT00059748
25 Pathogenic Studies In Families With Twins Or Siblings Discordant For Systemic Rheumatic Disorders Recruiting NCT00055055
26 MYOPROSP: A Prospective Cohort Study to Identify a Stratified Approach in the Diagnosis, Treatment and Delivery of Care in Adult Idiopathic Inflammatory Myopathy Recruiting NCT02468895
27 Compassionate Use Treatment Protocol I4V-MC-JAGA: Treatment of Conditions Expected to Benefit From JAK 1/2 Inhibition: CANDLE, CANDLE-Related Conditions, SAVI and Severe Juvenile Dermatomyositis No longer available NCT01724580 Baricitinib

Search NIH Clinical Center for Childhood Type Dermatomyositis

Genetic Tests for Childhood Type Dermatomyositis

Anatomical Context for Childhood Type Dermatomyositis

MalaCards organs/tissues related to Childhood Type Dermatomyositis:

40
Skeletal Muscle, Skin, Bone, Heart, Lung, T Cells, B Cells

Publications for Childhood Type Dermatomyositis

Articles related to Childhood Type Dermatomyositis:

(showing 1086, show less)
# Title Authors PMID Year
1
Treatment of calcinosis cutis in systemic sclerosis and dermatomyositis: A review of the literature. 61
31302187 2020
2
Adenosine deaminase 2 as a biomarker of macrophage activation syndrome in systemic juvenile idiopathic arthritis. 61
31707357 2020
3
Severe Abdominal Manifestations in Juvenile Dermatomyositis. 61
31978027 2020
4
Growth and Puberty in Juvenile Dermatomyositis: A Longitudinal Cohort Study. 61
31507092 2020
5
Neutrophil Extracellular Traps in Tissue and Periphery in Juvenile Dermatomyositis. 61
31403247 2020
6
Clinical practice guidance for juvenile dermatomyositis (JDM) 2018-Update. 61
31955618 2020
7
Visual Dermatology: Gottron Papules in a Child: Juvenile Dermatomyositis. 61
31994926 2020
8
Juvenile Dermatomyositis and Development of Malignancy: 2 Case Reports and a Literature Review. 61
31941800 2020
9
Hypopigmentation in the Medial Angle of Eyes in a Young Boy With Juvenile Dermatomyositis. 61
31977652 2020
10
Case Report of a Rare Case of Juvenile Dermatomyositis Sine Dermatitis. 61
31979712 2020
11
Inhibition of IFNα secretion in cells from patients with juvenile dermatomyositis under TBK1 inhibitor treatment revealed by single-molecular assay technology. 61
31971592 2020
12
Scrotal and Penile Ulcer in Juvenile Dermatomyositis: An Unusual Occurrence. 61
29561468 2020
13
Patient and physician discordance of global disease assessment in juvenile dermatomyositis: findings from the Childhood Arthritis & Rheumatology Research Alliance Legacy Registry. 61
31941511 2020
14
Juvenile dermatomyositis resembling late-stage Degos disease with gastrointestinal perforations successfully treated with combination of cyclophosphamide and rituximab: case-based review. 61
31900501 2020
15
Pamidronate in Treatment of Calcinosis in Juvenile Dermatomyositis. 61
31937708 2020
16
Using peripheral blood immune signatures to stratify patients with adult and juvenile inflammatory myopathies. 61
31292651 2020
17
Juvenile Dermatomyositis-Clinical Phenotypes. 61
31828535 2019
18
Strength training and aerobic exercise training for muscle disease. 61
31808555 2019
19
Long-term outcome in children with juvenile dermatomyositis: A single-center study from north India. 61
31793219 2019
20
Distinct interferon signatures and cytokine patterns define additional systemic autoinflammatory diseases. 61
31874111 2019
21
Epidemiology of juvenile dermatomyositis in Alsace. 61
31823358 2019
22
Advances Toward Precision Medicine in Juvenile Dermatomyositis. 61
31813083 2019
23
[Three cases report of juvenile dermatomyositis with positive anti-melanoma differentiation associated gene 5 (MDA5) antibody and severe interstitial lung disease and literature review]. 61
31795559 2019
24
Association of Short-Term Ultraviolet Radiation Exposure and Disease Severity in Juvenile Dermatomyositis: Results From the Childhood Arthritis and Rheumatology Research Alliance Legacy Registry. 61
30714338 2019
25
Juvenile dermatomyositis and pneumomediastinum: a case of a very rare complication. 61
31883798 2019
26
Pain, functional disability, and their Association in Juvenile Fibromyalgia Compared to other pediatric rheumatic diseases. 61
31694655 2019
27
Reply: Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib. 61
31603183 2019
28
An international survey of developing classification criteria for juvenile dermatomyositis-scleroderma overlap. 61
31199482 2019
29
Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib. 61
31603187 2019
30
Polymyxin-B Hemoperfusion as a Novel Treatment for Rapidly Progressive Interstitial Lung Disease in a Pediatric Patient Diagnosed With Anti-MDA5 Juvenile Dermatomyositis. 61
31743264 2019
31
Using the tools of proteomics to understand the pathogenesis of idiopathic inflammatory myopathies. 61
31385878 2019
32
Functional and Structural Adaptations of Skeletal Muscle in Long-Term Juvenile Dermatomyositis; a Controlled Cross-Sectional Study. 61
31746550 2019
33
Treatment of calcinosis associated with adult and juvenile dermatomyositis using topical sodium thiosulfate via fractionated CO2 laser treatment. 61
31796160 2019
34
Severe Abdominal Manifestations in Juvenile Dermatomyositis. 61
31789774 2019
35
Serum KL-6 level as a biomarker of interstitial lung disease in childhood connective tissue diseases: a pilot study. 61
31784789 2019
36
Novel associations between cytokines and pulmonary involvement in juvenile dermatomyositis - a cross-sectional study of long-term disease. 61
31740970 2019
37
Calcinosis in Juvenile Dermatomyositis. 61
31618543 2019
38
Vaccination coverage in children with rheumatic diseases. 61
31577215 2019
39
Image Gallery: Antihelix red-violaceous macules in juvenile dermatomyositis associated with antimelanoma differentiation-associated protein 5 antibody. 61
31598963 2019
40
Inhibition of IFNα secretion in cells from patients with juvenile dermatomyositis under TBK1 inhibitor treatment revealed by single-molecular assay technology. 61
31665500 2019
41
Tertiary lymphoid organs in the inflammatory myopathy associated with PD-1 inhibitors. 61
31533865 2019
42
Juvenile dermatomyositis associated with anti-melanoma differentiation-associated gene 5 antibody positivity without complications of interstitial lung disease during the clinical course: A case report. 61
30869164 2019
43
[Pediatric and adolescent rheumatology-A rapidly developing field in pediatrics : Current status of juvenile idiopathic arthritis and juvenile dermatomyositis]. 61
31482211 2019
44
Macrophage activation syndrome in juvenile dermatomyositis: a systematic review. 61
31529231 2019
45
Clinical significance of subcutaneous fat and fascial involvement in juvenile dermatomyositis. 61
30092673 2019
46
Prevalence of Epstein-Barr virus infection and characteristics of lymphocyte subsets in newly onset juvenile dermatomyositis. 61
31549298 2019
47
Subcutaneous edema in juvenile dermatomyositis. 61
28709855 2019
48
Juvenile dermatomyositis: advances in clinical presentation, myositis-specific antibodies and treatment. 61
31556011 2019
49
[Juvenile dermatomyositis-what's new?] 61
31087132 2019
50
Clinical subsets of juvenile dermatomyositis classified by myositis-specific autoantibodies: Experience at a single center in Japan. 61
30092736 2019
51
Unusual cause for intestinal perforation in juvenile dermatomyositis. 61
31444261 2019
52
Galectin-9 and CXCL10 as Biomarkers for Disease Activity in Juvenile Dermatomyositis: A Longitudinal Cohort Study and Multicohort Validation. 61
30861625 2019
53
Endothelial Activation Markers as Disease Activity and Damage Measures in Juvenile Dermatomyositis. 61
31371656 2019
54
Symmetrical cutaneous ulcers: Are they associated with severe disease in children with juvenile dermatomyositis? 61
31449488 2019
55
The identification of CCL18 as biomarker of disease activity in localized scleroderma. 61
31006523 2019
56
The prevention and treatment of glucocorticoid-induced osteopaenia in juvenile rheumatic disease: A randomised double-blind controlled trial. 61
31388666 2019
57
Patchy Lipodystrophy in a Young Adult With Juvenile Dermatomyositis: An Unusual Occurrence. 61
31356391 2019
58
Development and validation of a composite disease activity score for measurement of muscle and skin involvement in juvenile dermatomyositis. 61
30690571 2019
59
Plasma exosomes from children with juvenile dermatomyositis are taken up by human aortic endothelial cells and are associated with altered gene expression in those cells. 61
31299993 2019
60
Juvenile polymyositis associated with ureteral necrosis: a diagnostic and therapeutic dilemma-case report and review of the literature. 61
31098736 2019
61
Erythematous scaling lesions of the face, dorsal fingers, elbows, and knees together with symmetrical muscle weakness in a child. 61
31360483 2019
62
Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis. 61
31018961 2019
63
Expression of myxovirus-resistance protein A: a possible marker of muscle disease activity and autoantibody specificities in juvenile dermatomyositis. 61
29770465 2019
64
Sex Differences in Pediatric Rheumatology. 61
28849549 2019
65
Paediatric and adolescent rheumatic diseases: measures of disease activity. 61
31180784 2019
66
Muscle Expression of Type I and Type II Interferons Is Increased in Juvenile Dermatomyositis and Related to Clinical and Histologic Features. 61
30552836 2019
67
Being on the juvenile dermatomyositis rollercoaster: a qualitative study. 61
31215480 2019
68
The PRINTO evidence-based proposal for glucocorticoids tapering/discontinuation in new onset juvenile dermatomyositis patients. 61
31118099 2019
69
Rheumatology Panel in Pediatric Practice. 61
31102381 2019
70
Interferon Chemokine Score and Other Cytokine Measures Track With Changes in Disease Activity in Patients With Juvenile and Adult Dermatomyositis. 61
31777784 2019
71
Association Between Nailfold Capillary Density and Pulmonary and Cardiac Involvement in Medium to Longstanding Juvenile Dermatomyositis. 61
29953739 2019
72
[Cognitive dysfunction, loss of visual acuity and hearing can be symptoms of Susac syndrome]. 61
30990159 2019
73
Translation and validation of the Transition Readiness Assessment Questionnaire (TRAQ). 61
29457995 2019
74
Incidence and Prevalence of Idiopathic Inflammatory Myopathies in Korea: a Nationwide Population-based Study. 61
30833879 2019
75
Cardiorespiratory fitness in long-term juvenile dermatomyositis: a controlled, cross-sectional study of active/inactive disease. 61
30508195 2019
76
Janus kinase 1/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis. 61
30715143 2019
77
Reply: Janus kinase 1/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis. 61
30715158 2019
78
Juvenile dermatomyositis with IgA nephropathy: case-based review. 61
30552457 2019
79
Myositis-specific autoantibodies in Japanese patients with juvenile idiopathic inflammatory myopathies. 61
29532710 2019
80
French expert opinion for the management of juvenile dermatomyositis. 61
30638764 2019
81
Modelling disease activity in juvenile dermatomyositis: A Bayesian approach. 61
28589751 2019
82
Multispecialty approach for improving outcomes in juvenile dermatomyositis. 61
31213823 2019
83
ASYMPTOMATIC MULTIFOCAL PARACENTRAL ACUTE MIDDLE MACULOPATHY ASSOCIATED WITH JUVENILE DERMATOMYOSITIS: OPTICAL COHERENCE ANGIOGRAPHY FINDINGS. 61
30614926 2019
84
Superior Mesenteric Artery Syndrome in a Case of Juvenile Dermatomyositis: A Unique Complication. 61
30664541 2019
85
A review of accelerometer-derived physical activity in the idiopathic inflammatory myopathies. 61
31660533 2019
86
Juvenile idiopathic inflammatory myopathies: A clinicopathological study with emphasis on muscle histology. 61
30706861 2019
87
Identification of Potential Biomarkers and Biological Pathways in Juvenile Dermatomyositis Based on miRNA-mRNA Network. 61
31886250 2019
88
B Cells as a Therapeutic Target in Paediatric Rheumatic Disease. 61
30837988 2019
89
Connective Tissue Disorders in Childhood: Are They All the Same? 61
30620697 2019
90
Coronary artery dilation associated with anti-synthetase syndrome in an adolescent. 61
30630507 2019
91
An Autopsy Case of a 5-Year-Old Child with Acute Pancreatitis Caused by Eosinophilic Granulomatosis with Polyangiitis-like Necrotizing Vasculitis. 61
31565459 2019
92
Targeting Tregs in Juvenile Idiopathic Arthritis and Juvenile Dermatomyositis-Insights From Other Diseases. 61
30740105 2019
93
Co-existence of Juvenile dermatomyositis and psoriasis vulgaris with fungal infection: A case report and literature review. 61
30697901 2019
94
Juvenile Dermatomyositis: A Case Report and Review of Literature. 61
30937233 2019
95
Off-label use of tocilizumab to treat non-juvenile idiopathic arthritis in pediatric rheumatic patients: a literature review. 61
30547812 2018
96
Serum biomarkers of glucocorticoid response and safety in anti-neutrophil cytoplasmic antibody-associated vasculitis and juvenile dermatomyositis. 61
30352204 2018
97
Medications received by patients with juvenile dermatomyositis. 61
29773230 2018
98
Clinical phenotypes and biologic treatment use in juvenile dermatomyositis-associated calcinosis. 61
30594206 2018
99
Pattern of myogenesis and vascular repair in early and advanced lesions of juvenile dermatomyositis. 61
30389421 2018
100
Update on the clinical management of juvenile dermatomyositis. 61
30308133 2018
101
Reply: A child with severe juvenile dermatomyositis treated with ruxolitinib. 61
30335129 2018
102
A child with severe juvenile dermatomyositis treated with ruxolitinib. 61
30335130 2018
103
Standardising measures in pediatric rheumatology: the experience of the international consensus dataset for juvenile dermatomyositis. 61
30613608 2018
104
Long-term follow-up of autologous hematopoietic stem cell transplantation for refractory juvenile dermatomyositis: a case-series study. 61
30458860 2018
105
Features distinguishing clinically amyopathic juvenile dermatomyositis from juvenile dermatomyositis. 61
30016492 2018
106
Increased Soluble Cytoplasmic Bcl-2 Protein Serum Levels and Expression and Decreased Fas Expression in Lymphocytes and Monocytes in Juvenile Dermatomyositis. 61
30068766 2018
107
Juvenile dermatomyositis: novel treatment approaches and outcomes. 61
30124602 2018
108
Dysregulated NK cell PLCγ2 signaling and activity in juvenile dermatomyositis. 61
30429375 2018
109
Inpatient burden of juvenile dermatomyositis among children in the United States. 61
30424778 2018
110
Fashionably Late: A Case of Delayed Cutaneous Manifestations in Juvenile Dermatomyositis. 61
30344821 2018
111
[Myositis-specific antibodies associated with juvenile dermatomyositis]. 61
29411095 2018
112
[Recent Developments in Myositis Syndromes]. 61
30286497 2018
113
Juvenile dermatomyositis forty years on: Case report. 61
30064892 2018
114
Expression of the OAS Gene Family Is Highly Modulated in Subjects Affected by Juvenile Dermatomyositis, Resembling an Immune Response to a dsRNA Virus Infection. 61
30227596 2018
115
Development and Testing of a Hybrid Measure of Muscle Strength in Juvenile Dermatomyositis for Use in Routine Care. 61
29245175 2018
116
Periorbital Edema as the Initial Sign of Juvenile Dermatomyositis. 61
30234551 2018
117
[Juvenile Dermatomyositis]. 61
29698985 2018
118
Panniculitis, A Rare Presentation of Onset and Exacerbation of Juvenile Dermatomyositis: A Case Report and Literature Review. 61
30632528 2018
119
Introduction of a novel magnetic resonance imaging-based scoring system for assessing disease activity in children with juvenile dermatomyositis. 61
29901756 2018
120
Juvenile dermatomyositis: is periodontal disease associated with dyslipidemia? 61
30657104 2018
121
Juvenile Idiopathic Inflammatory Myopathies. 61
30031496 2018
122
Whole-body magnetic resonance imaging: techniques and non-oncologic indications. 61
30078041 2018
123
Clinical signs and symptoms in a joint model of four disease activity parameters in juvenile dermatomyositis: a prospective, longitudinal, multicenter cohort study. 61
30111380 2018
124
Treatment With Rituximab in Juvenile Dermatomyositis: Effect on Calcinosis. 61
30054253 2018
125
Juvenile Dermatomyositis: Key Roles of Muscle Magnetic Resonance Imaging and Early Aggressive Treatment. 61
28911766 2018
126
Inverse Gottron papules in juvenile dermatomyositis: an under recognized clinical entity. 61
29721695 2018
127
Development of practice and consensus-based strategies including a treat-to-target approach for the management of moderate and severe juvenile dermatomyositis in Germany and Austria. 61
29940960 2018
128
Current management of juvenile dermatomyositis in Germany and Austria: an online survey of pediatric rheumatologists and pediatric neurologists. 61
29925381 2018
129
A Bayesian semiparametric Markov regression model for juvenile dermatomyositis. 61
29462840 2018
130
Anti-NT5C1A autoantibodies are associated with more severe disease in patients with juvenile myositis. 61
29363513 2018
131
Muscle ischaemia associated with NXP2 autoantibodies: a severe subtype of juvenile dermatomyositis. 61
29474663 2018
132
Assessment of Microvascular Abnormalities by Nailfold Capillaroscopy in Juvenile Dermatomyositis After Medium- to Long-Term Followup. 61
28805016 2018
133
Efficacy and Safety of Cyclophosphamide Treatment in Severe Juvenile Dermatomyositis Shown by Marginal Structural Modeling. 61
29342499 2018
134
Innovative Research Design to Meet the Challenges of Clinical Trials for Juvenile Dermatomyositis. 61
29637406 2018
135
Multiple target autoantigens on endothelial cells identified in juvenile dermatomyositis using proteomics. 61
29361142 2018
136
Correction: 2016 American college of rheumatology/European league against rheumatism criteria for minimal moderate, and major clinical response in juvenile dermatomyositis. 61
29530915 2018
137
Cardiovascular and cerebrovascular comorbidities of juvenile dermatomyositis in US children: an analysis of the National Inpatient Sample. 61
29373707 2018
138
Predictors of changes in disease activity among children with juvenile dermatomyositis enrolled in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Legacy Registry. 61
29170979 2018
139
Advances in Juvenile Dermatomyositis: Myositis Specific Antibodies Aid in Understanding Disease Heterogeneity. 61
29576174 2018
140
Comparing the importance of quality measurement themes in juvenile idiopathic inflammatory myositis between patients and families and healthcare professionals. 61
29673367 2018
141
Imaging Features of the Juvenile Inflammatory Arthropathies. 61
29672804 2018
142
Koebner Phenomenon in Juvenile Dermatomyositis. 61
29496916 2018
143
Focal hyperkeratosis overlying the palmar faces of interphalangeal and metacarpophalangeal joints revealing a juvenile dermatomyositis. 61
28895209 2018
144
Development of a consensus core dataset in juvenile dermatomyositis for clinical use to inform research. 61
29084729 2018
145
CD19+CD24hiCD38hi B Cells Are Expanded in Juvenile Dermatomyositis and Exhibit a Pro-Inflammatory Phenotype After Activation Through Toll-Like Receptor 7 and Interferon-α. 61
29988398 2018
146
Systemic and Tissue Inflammation in Juvenile Dermatomyositis: From Pathogenesis to the Quest for Monitoring Tools. 61
30619311 2018
147
Potential association of LMNA-associated generalized lipodystrophy with juvenile dermatomyositis. 61
29610677 2018
148
[Peripheral nervous system immunological disorder]. 61
30199371 2018
149
The Vasculopathy of Juvenile Dermatomyositis. 61
30356795 2018
150
Myogenic Progenitor Cells Exhibit Type I Interferon-Driven Proangiogenic Properties and Molecular Signature During Juvenile Dermatomyositis. 61
28941175 2018
151
A Viral Polymyositis Masquerade: Life-Threatening Case of Juvenile Dermatomyositis Complicated by Systemic Capillary Leak Syndrome. 61
29720802 2018
152
Extensive skin ulcers in a child with juvenile dermatomyositis. 61
29367373 2018
153
Retinal Manifestations of Juvenile Dermatomyositis: Case Report of Bilateral Diffuse Chorioretinopathy with Paracentral Acute Middle Maculopathy and Review of the Literature. 61
28448730 2018
154
Overlap syndrome: juvenile dermatomyositis and perinuclear antineutrophil cytoplasmic autoantibody vasculitis, a case report and review of literature. 61
28752636 2017
155
Trajectories of cardiorespiratory fitness in patients with juvenile dermatomyositis. 61
29029283 2017
156
The family impact of caring for a child with juvenile dermatomyositis. 61
28133992 2017
157
Recent clinical trials in idiopathic inflammatory myopathies. 61
28763333 2017
158
2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria-methodological aspects. 61
28977549 2017
159
Treatment of Juvenile Dermatomyositis: An Update. 61
28550457 2017
160
Life-threatening systemic capillary leak syndrome in juvenile dermatomyositis. 61
28957546 2017
161
Presentations and outcomes of juvenile dermatomyositis patients admitted to intensive care units. 61
28957568 2017
162
Evaluation of the reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index and the Cutaneous Assessment Tool-Binary Method in juvenile dermatomyositis among paediatric dermatologists, rheumatologists and neurologists. 61
28421601 2017
163
Assessment, classification and treatment of calcinosis as a complication of juvenile dermatomyositis: a survey of pediatric rheumatologists by the childhood arthritis and rheumatology research alliance (CARRA). 61
28934971 2017
164
Improvement of nailfold capillary microangiopathy after immunosuppressant therapy in a child with clinically amyopathic juvenile dermatomyositis. 61
29037322 2017
165
Devic's disease in an adolescent girl with juvenile dermatomyositis. 61
29037319 2017
166
Phenotypic characteristics and outcome of juvenile dermatomyositis in Arab children. 61
28685324 2017
167
Case of lipoatrophic diabetes induced by juvenile dermatomyositis. 61
28895299 2017
168
Juvenile dermatomyositis: Latest advances. 61
29773272 2017
169
First report of anti-TIF1γ dermatomyositis in a patient with myelodysplastic syndrome. 61
28776361 2017
170
Localized cutaneous immunoglobulin light chain kappa-positive amyloidosis associated with juvenile dermatomyositis. 61
28406528 2017
171
Genetic interferonopathies: An overview. 61
29773266 2017
172
Coexisting Juvenile Dermatomyositis and Sickle Cell Disease: Maintaining a High Degree of Suspicion. 61
28396024 2017
173
Clinical analysis and outcome of interstitial lung disease complicated with juvenile dermatomyositis and juvenile polymyositis. 61
27588444 2017
174
Cardiac findings in children with juvenile Dermatomyositis at disease presentation. 61
28693511 2017
175
Well-controlled juvenile dermatomyositis over 20 years recurred after delivery. 61
27542336 2017
176
Association of Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Autoantibodies With DRB1*07:01 and Severe Myositis in Juvenile Myositis Patients. 61
28129483 2017
177
Protecting Bone Health in Pediatric Rheumatic Diseases: Pharmacological Considerations. 61
28290112 2017
178
Submaximal Exercise Capacity in Juvenile Dermatomyositis after Longterm Disease: The Contribution of Muscle, Lung, and Heart Involvement. 61
28365577 2017
179
Juvenile dermatomyositis/polymyositis and lymphoma. 61
28477693 2017
180
The Use of Cyclosporine A in Rheumatology: a 2016 Comprehensive Review. 61
27515671 2017
181
Biologic therapies for refractory juvenile dermatomyositis: five years of experience of the Childhood Arthritis and Rheumatology Research Alliance in North America. 61
28610606 2017
182
Axillary Skin Ulcers in Infants with Juvenile Dermatomyositis. 61
27733312 2017
183
Physical activity for paediatric rheumatic diseases: standing up against old paradigms. 61
28533552 2017
184
Varicella vaccination elicits a humoral and cellular response in children with rheumatic diseases using immune suppressive treatment. 61
28412076 2017
185
Race and income affects outcomes in juvenile dermatomyositis. 61
28434566 2017
186
Validation of International Classification of Diseases Codes for the Epidemiologic Study of Dermatomyositis. 61
27564726 2017
187
Endothelial progenitor cell number is not decreased in 34 children with Juvenile Dermatomyositis: a pilot study. 61
28514969 2017
188
Race, Income, and Disease Outcomes in Juvenile Dermatomyositis. 61
28410093 2017
189
Autoantibodies in children with juvenile dermatomyositis: A single centre experience from North-West India. 61
28331982 2017
190
2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. 61
28385804 2017
191
2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. 61
28382778 2017
192
Association between demyelinating disease and autoimmune rheumatic disease in a pediatric population. 61
28535894 2017
193
Muscle MRI at the time of questionable disease flares in Juvenile Dermatomyositis (JDM). 61
28403889 2017
194
Profile of Pediatric Idiopathic Inflammatory Myopathies from a Tertiary Care Center of Eastern India. 61
28251541 2017
195
Successful Treatment of Refractory Juvenile Dermatomyositis With Adalimumab. 61
28333871 2017
196
The Expanding Spectrum of Gottron Papules in Juvenile Dermatomyositis. 61
27924465 2017
197
A Rare Case of Amyopathic Juvenile Dermatomyositis Associated With Psoriasis Successfully Treated With Ustekinumab. 61
28099216 2017
198
Methods for analyzing observational longitudinal prognosis studies for rheumatic diseases: a review & worked example using a clinic-based cohort of juvenile dermatomyositis patients. 61
28356102 2017
199
Assessment of Type I Interferon Signaling in Pediatric Inflammatory Disease. 61
27943079 2017
200
Beyond the MHC: A canine model of dermatomyositis shows a complex pattern of genetic risk involving novel loci. 61
28158183 2017
201
Trachyonychia in juvenile dermatomyositis: nail as a mirror to disease activity. 61
27677537 2017
202
Juvenile dermatomyositis in a 4-year-old Kenyan girl. 61
28174638 2017
203
Consensus-based recommendations for the management of juvenile dermatomyositis. 61
27515057 2017
204
Juvenile dermatomyositis positive for anti-DNA mismatch repair enzyme antibodies. 61
28073708 2017
205
Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab. 61
27837048 2017
206
Idiopathic Inflammatory Myopathies: an Update on Classification and Treatment with Special Focus on Juvenile Forms. 61
26429707 2017
207
Juvenile dermatomyositis: a tertiary center experience. 61
28058540 2017
208
Contraception for adolescents with chronic rheumatic diseases. 61
28137405 2017
209
Childhood Arthritis and Rheumatology Research Alliance consensus clinical treatment plans for juvenile dermatomyositis with skin predominant disease. 61
28077146 2017
210
Spectrum of paediatric rheumatic diseases in Nigeria. 61
28143550 2017
211
Intravenous Immunoglobulin in Pediatric Rheumatology: When to Use It and What Is the Evidence. 61
28079914 2017
212
Childhood Arthritis and Rheumatology Research Alliance Consensus Clinical Treatment Plans for Juvenile Dermatomyositis with Persistent Skin Rash. 61
27803135 2017
213
Recurrent Multiple Squamous Cell Carcinomas on the Scalp in a Patient with Juvenile Dermatomyositis. 61
28203172 2017
214
How Often are Pediatric Patients with Clinically Amyopathic Dermatomyositis Truly Amyopathic? 61
27813167 2017
215
Recurrence of juvenile dermatomyositis 8 years after remission. 61
28050594 2017
216
Validity of the Stage of Exercise Scale in Children with Rheumatologic Conditions. 61
27803137 2016
217
Acute Presentation of Juvenile Dermatomyositis with Subclinical Cardiac Involvement: A Rare Case. 61
28208969 2016
218
Analysis of CXCR5+Th17 cells in relation to disease activity and TNF inhibitor therapy in Rheumatoid Arthritis. 61
28004828 2016
219
[What's new in internal medecine?] 61
29429506 2016
220
Muscle Biopsy Findings in Combination With Myositis-Specific Autoantibodies Aid Prediction of Outcomes in Juvenile Dermatomyositis. 61
27214289 2016
221
Characteristics and outcome of children with juvenile dermatomyositis in Cape Town: a cross-sectional study. 61
27835954 2016
222
Juvenile dermatomyositis: new clinical trial evidence to underpin therapeutic shared decision making. 61
27650736 2016
223
[Role of magnetic resonance imaging in the diagnosis of juvenile dermato-myositis and polymyositis in Chinese children]. 61
27784480 2016
224
Comparison of the Utility and Validity of Three Scoring Tools to Measure Skin Involvement in Patients With Juvenile Dermatomyositis. 61
26881696 2016
225
[Juvenile dermatomyositis: Early onset and unusual presentation]. 61
27622296 2016
226
Information technology in paediatric rheumatology. 61
27762188 2016
227
Gene copy-number variations (CNVs) of complement C4 and C4A deficiency in genetic risk and pathogenesis of juvenile dermatomyositis. 61
26493816 2016
228
Treatment with high-dose recombinant human hyaluronidase-facilitated subcutaneous immune globulins in patients with juvenile dermatomyositis who are intolerant to intravenous immune globulins: a report of 5 cases. 61
27623619 2016
229
Respiratory complications of the rheumatological diseases in childhood. 61
26768831 2016
230
The impact of underlying disease on fracture risk and bone mineral density in children with rheumatic disorders: A review of current literature. 61
27020068 2016
231
A case of anti-nuclear matrix protein 2 antibody positive myopathy associated with lung cancer. 61
27477574 2016
232
Panniculitis in juvenile dermatomyositis: Report of a case and review of the published work. 61
26971888 2016
233
Physical (in)activity and its influence on disease-related features, physical capacity, and health-related quality of life in a cohort of chronic juvenile dermatomyositis patients. 61
27113390 2016
234
Muscles in motion: a randomized controlled trial on the feasibility, safety and efficacy of an exercise training programme in children and adolescents with juvenile dermatomyositis. 61
27018060 2016
235
The Importance of Computed Tomography for the Diagnosis Of Duodenal Perforation in a Paediatric Patient with Juvenile Dermatomyositis. 61
27362413 2016
236
Calcinosis in juvenile dermatomyositis: frequency, risk factors and outcome. 61
27007612 2016
237
The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes. 61
27028907 2016
238
Myositis-specific and myositis-associated autoantibodies in Indian patients with inflammatory myositis. 61
27193471 2016
239
[New insights of myositis-specific and -associated autoantibodies in juvenile and adult type myositis]. 61
27452067 2016
240
Poor agreement of objectively measured and self-reported physical activity in juvenile dermatomyositis and juvenile systemic lupus erythematosus. 61
27021334 2016
241
The PRINTO juvenile dermatomyositis trial - Authors' reply. 61
27353819 2016
242
The PRINTO juvenile dermatomyositis trial. 61
27353816 2016
243
Simultaneous muscle water T2 and fat fraction mapping using transverse relaxometry with stimulated echo compensation. 61
26814454 2016
244
Subcutaneous Immunoglobulin in Refractory Juvenile Dermatomyositis. 61
26966131 2016
245
Heliotrope Rash and Gottron Papules in a Child with Juvenile Dermatomyositis. 61
26817590 2016
246
Exhaled breath analysis in childhood rheumatic disorders--a longitudinal study. 61
27093271 2016
247
[Connective tissue diseases in adolescents]. 61
27000182 2016
248
Juvenile dermatomyositis with anti-signal recognition particle antibodies: a case report. 61
27606477 2016
249
Severe gluteal skin ulcers in an infant with juvenile dermatomyositis. 61
26712099 2016
250
Detection of anti-p155/140, anti-p140, and antiendothelial cells autoantibodies in patients with juvenile dermatomyositis. 61
25070283 2016
251
In juvenile dermatomyositis, heart rate variability is reduced, and associated with both cardiac dysfunction and markers of inflammation: a cross-sectional study median 13.5 years after symptom onset. 61
26500284 2016
252
Vasculopathy-related clinical and pathological features are associated with severe juvenile dermatomyositis. 61
26424834 2016
253
Familial autoimmunity in the Childhood Arthritis and Rheumatology Research Alliance registry. 61
26965173 2016
254
Calcinosis in juvenile dermatomyositis mimicking cold abscess. 61
27586213 2016
255
Progress in the treatment of juvenile dermatomyositis. 61
26645191 2016
256
Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial. 61
26645190 2016
257
A Practical Approach to Juvenile Dermatomyositis and Juvenile Scleroderma. 61
26489640 2016
258
Juvenile dermatomyositis: A report of three cases. 61
26886841 2016
259
Autologous stem cell transplantation aids autoimmune patients by functional renewal and TCR diversification of regulatory T cells. 61
26480932 2016
260
Pneumatosis Intestinalis Associated with Juvenile Dermatomyositis. 61
27242944 2016
261
Efficacy and safety of creatine supplementation in juvenile dermatomyositis: A randomized, double-blind, placebo-controlled crossover trial. 61
25899989 2016
262
MicroRNA-10a Regulation of Proinflammatory Mediators: An Important Component of Untreated Juvenile Dermatomyositis. 61
26628598 2016
263
Increased Serum B Cell Activating Factor and a Proliferation-inducing Ligand Are Associated with Interstitial Lung Disease in Patients with Juvenile Dermatomyositis. 61
26472413 2015
264
Autoantibodies to Dense Fine Speckles in Pediatric Diseases and Controls. 61
26472409 2015
265
Patients' Experience of Myositis and Further Validation of a Myositis-specific Patient Reported Outcome Measure - Establishing Core Domains and Expanding Patient Input on Clinical Assessment in Myositis. Report from OMERACT 12. 61
25934817 2015
266
[Juvenile dermatomyositis and new autoantibodies: Cases and review]. 61
26598044 2015
267
Muscle Metabolic Responses During Dynamic In-Magnet Exercise Testing: A Pilot Study in Children with an Idiopathic Inflammatory Myopathy. 61
26259546 2015
268
A Report of Three Cases With Acquired Generalized Lipodystrophy With Distinct Autoimmune Conditions Treated With Metreleptin. 61
26390101 2015
269
Successful control of juvenile dermatomyositis-associated macrophage activation syndrome and interstitial pneumonia: distinct kinetics of interleukin-6 and -18 levels. 61
26581448 2015
270
Quantitative muscle ultrasonography in the follow-up of juvenile dermatomyositis. 61
25557638 2015
271
Genome-wide association study identifies HLA 8.1 ancestral haplotype alleles as major genetic risk factors for myositis phenotypes. 61
26291516 2015
272
Methotrexate polyglutamates as a potential marker of adherence to long-term therapy in children with juvenile idiopathic arthritis and juvenile dermatomyositis: an observational, cross-sectional study. 61
26493320 2015
273
Juvenile dermatomyositis with joint contractures and calcinosis cutis. 61
26632806 2015
274
[Clinical features of patients with juvenile and adult dermatomyositis]. 61
26552025 2015
275
Analysis of Published Criteria for Clinically Inactive Disease in a Large Juvenile Dermatomyositis Cohort Shows That Skin Disease Is Underestimated. 61
25988361 2015
276
Recovery of Severe Muscular and Fascial Calcinosis After Treatment With Bisphosphonates in a Child With Juvenile Dermatomyositis. 61
26203832 2015
277
Juvenile Dermatomyositis: A Case of Calcinosis Cutis of the Elbow and Review of the Literature. 61
25412072 2015
278
Bisphosphonates in juvenile dermatomyositis with dystrophic calcinosis. 61
25800510 2015
279
Juvenile dermatomyositis without skin lesions. 61
26622984 2015
280
Panniculitis in juvenile dermatomyositis. 61
25682744 2015
281
[JUVENILE DERMATOMYOSITIS AND CALCINOSIS]. 61
26177136 2015
282
Development of an internationally agreed minimal dataset for juvenile dermatomyositis (JDM) for clinical and research use. 61
26063230 2015
283
[Importance of a full assessment in patients diagnosed with juvenile dermatomyositis]. 61
25746608 2015
284
Palmoplantar hyperkeratosis: a rare cutaneous manifestation of juvenile dermatomyositis. 61
25782089 2015
285
[Dermatomyositis-specific antibodies]. 61
25644067 2015
286
Advances in biomarkers for paediatric rheumatic diseases. 61
25512012 2015
287
Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis. 61
25288783 2015
288
Treatment and clinical outcome of juvenile dermatomyositis. 61
25487198 2015
289
Juvenile dermatomyositis: a 20-year retrospective analysis of treatment and clinical outcomes. 61
24985888 2015
290
Calcinosis Universalis of the Elbow: A Rare Case with Classical Presentation. 61
26579322 2015
291
Adipokine gene expression in peripheral blood of adult and juvenile dermatomyositis patients and their relation to clinical parameters and disease activity measures. 61
25918482 2015
292
Cardiovascular involvement in pediatric systemic autoimmune diseases: the emerging role of noninvasive cardiovascular imaging. 61
25778740 2015
293
Dramatic Improvement of Subcutaneous Calcinosis by Intermittent, High-Dose Etidronate plus Cimetidine in a Patient with Juvenile Dermatomyositis. 61
26640735 2015
294
[Dermatomyositis. Presentation of a mild to moderate case with early dysphagia]. 61
24529890 2015
295
[Devic's disease in an adolescent girl with juvenile dermatomyositis]. 61
25772655 2015
296
Validation of a score tool for measurement of histological severity in juvenile dermatomyositis and association with clinical severity of disease. 61
24064003 2015
297
Using proteomic and genomic methods to understand JDM. 61
26213193 2015
298
Autologous stem cell transplantation leads to a change in proinflammatory plasma cytokine profile of patients with juvenile dermatomyositis correlating with disease activity. 61
25269830 2015
299
In active juvenile dermatomyositis, elevated eotaxin and MCP-1 and cholesterol levels in the upper normal range are associated with cardiac dysfunction. 61
24996906 2014
300
Successful treatment of calcinosis cutis in juvenile dermatomyositis with pamidronate. 61
25417690 2014
301
Radiographic patterns of soft tissue calcinosis in juvenile dermatomyositis and its clinical implications. 61
25654011 2014
302
The presentation, assessment, pathogenesis, and treatment of calcinosis in juvenile dermatomyositis. 61
25366934 2014
303
The evolving spectrum of polymyositis and dermatomyositis--moving towards clinicoserological syndromes: a critical review. 61
24048686 2014
304
Four dermatomyositis-specific autoantibodies-anti-TIF1γ, anti-NXP2, anti-SAE and anti-MDA5-in adult and juvenile patients with idiopathic inflammatory myopathies in a Hungarian cohort. 61
25182203 2014
305
Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset. 61
24987158 2014
306
Autoantibodies to DNA mismatch repair enzymes in polymyositis/dermatomyositis and other autoimmune diseases: a possible marker of favorable prognosis. 61
25186186 2014
307
Lower extremity lipedema, upper extremity lipodystrophy and severe calcinosis complicating juvenile dermatomyositis. 61
24789670 2014
308
A hyper-ferritinemia syndrome evolving in recurrent macrophage activation syndrome, as an onset of amyopathic juvenile dermatomyositis: a challenging clinical case in light of the current diagnostic criteria. 61
24879966 2014
309
Therapy of myositis: biological and physical. 61
25198241 2014
310
Recent advances in juvenile idiopathic inflammatory myopathies. 61
25160931 2014
311
Severe calcinosis cutis with cutaneous ulceration in juvenile dermatomyositis. 61
25432230 2014
312
Nailfold capillaroscopy in juvenile rheumatic diseases: known measures, patterns and indications. 61
24960119 2014
313
Mortality in children with juvenile dermatomyositis: two decades of experience from a single tertiary care centre in North India. 61
25053380 2014
314
Republished: new age of biological therapies in paediatric rheumatology. 61
25230947 2014
315
Risk factors for juvenile dermatomyositis: exposure to tobacco and air pollutants during pregnancy. 61
24757124 2014
316
A case of adult dermatomyositis with calcinosis universalis. 61
25400376 2014
317
In juvenile dermatomyositis, cardiac systolic dysfunction is present after long-term follow-up and is predicted by sustained early skin activity. 61
23881732 2014
318
An update on juvenile dermatomyositis. 61
25034096 2014
319
Acute acalculous cholecystitis in a patient with juvenile dermatomyositis. 61
25239990 2014
320
Disease activity and prognostic factors in juvenile dermatomyositis: a long-term follow-up study applying the Paediatric Rheumatology International Trials Organization criteria for inactive disease and the myositis disease activity assessment tool. 61
24692575 2014
321
Novel assessment tools to evaluate clinical and laboratory responses in a subset of patients enrolled in the Rituximab in Myositis trial. 61
25068290 2014
322
HIV with juvenile dermatomyositis. 61
23881481 2014
323
Nodular cystic fat necrosis with calcification in a patient with juvenile dermatomyositis. 61
24930439 2014
324
Dermatomyositis: analysis of 109 patients surveyed at the Hospital das Clínicas (HCFMUSP), São Paulo, Brazil. 61
25184910 2014
325
Clinical course and outcomes of Iranian children with juvenile dermatomyositis and polymyositis. 61
24878926 2014
326
Correlation of CXCL10, tumor necrosis factor receptor type II, and galectin 9 with disease activity in juvenile dermatomyositis. 61
24756983 2014
327
New age of biological therapies in paediatric rheumatology. 61
24621445 2014
328
Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study. 61
24989778 2014
329
[Periodontal disease in pediatric rheumatic diseases]. 61
25627227 2014
330
[Lung is also involved in juvenile dermatomyositis]. 61
24856457 2014
331
Long-term, high-dose intravenous immunoglobulin therapy in a patient with banker-type juvenile dermatomyositis. 61
24500836 2014
332
Whole-body MRI in the assessment of disease activity in juvenile dermatomyositis. 61
23636654 2014
333
Pilot study of etanercept in patients with refractory juvenile dermatomyositis. 61
24127327 2014
334
Early illness features associated with mortality in the juvenile idiopathic inflammatory myopathies. 61
24151254 2014
335
Performance of the new SLICC classification criteria in childhood systemic lupus erythematosus: a multicentre study. 61
24642380 2014
336
Sodium thiosulfate for the treatment of calcinosis secondary to juvenile dermatomyositis. 61
24238152 2014
337
Health outcomes of pediatric rheumatic diseases. 61
24974066 2014
338
Role of activated macrophage and inflammatory cytokines in the development of calcinosis in juvenile dermatomyositis. 61
24191066 2014
339
Pulmonary function and autoantibodies in a long-term follow-up of juvenile dermatomyositis patients. 61
24310298 2014
340
Juvenile dermatomyositis in a Nigerian girl. 61
24706700 2014
341
Retrospective analysis of the outcome of patients with idiopathic inflammatory myopathy: a long-term follow-up study. 61
24447373 2014
342
Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. 61
24574235 2014
343
Clinical characteristics of children with juvenile dermatomyositis: the Childhood Arthritis and Rheumatology Research Alliance Registry. 61
23983017 2014
344
Onset of juvenile dermatomyositis following varicella infection in a 12-month-old child: a case report. 61
24529167 2014
345
[Importance of muscle biopsy in the diagnosis of juvenile dermatomyositis]. 61
23746465 2014
346
"Milk of calcium": a rare presentation of calcinosis. 61
24878795 2014
347
Radiological imaging in pediatric rheumatic diseases. 61
24669280 2014
348
Improvement of calcinosis using pamidronate in a patient with juvenile dermatomyositis. 61
23839717 2014
349
Severe macrophage activation syndrome and central nervous system involvement in juvenile dermatomyositis. 61
24588361 2014
350
Quantitative muscle ultrasound: a potential tool for assessment of disease activity in juvenile dermatomyositis. 61
24720507 2014
351
Increased presence of FOXP3+ regulatory T cells in inflamed muscle of patients with active juvenile dermatomyositis compared to peripheral blood. 61
25157414 2014
352
Juvenile dermatomyositis in South African children is characterised by frequent dystropic calcification: a cross sectional study. 61
24397895 2014
353
Increased levels of eotaxin and MCP-1 in juvenile dermatomyositis median 16.8 years after disease onset; associations with disease activity, duration and organ damage. 61
24647150 2014
354
Developing a provisional, international minimal dataset for Juvenile Dermatomyositis: for use in clinical practice to inform research. 61
25075205 2014
355
Whole-body magnetic resonance imaging in the assessment of muscular involvement in juvenile dermatomyositis/polymyositis patients. 61
25087579 2014
356
Unilateral heliotrope rash in juvenile dermatomyositis: an unusual presentation of an underlying serious disease. 61
25587479 2014
357
Autophagy, inflammation and innate immunity in inflammatory myopathies. 61
25365350 2014
358
Idiopathic inflammatory myopathies. 61
24365315 2014
359
Aerobic training in persons who have recovered from juvenile dermatomyositis. 61
24120572 2013
360
Introducing new tools for assessment of parent- and child-reported outcomes in paediatric rheumatology practice: a work in progress. 61
23981398 2013
361
Encephalopathic Susac's Syndrome associated with livedo racemosa in a young woman before the completion of family planning. 61
24274741 2013
362
Developments in the classification and treatment of the juvenile idiopathic inflammatory myopathies. 61
24182859 2013
363
Update in juvenile myositis. 61
24061078 2013
364
Lack of achievement of a full score on the childhood myositis assessment scale by healthy four-year-olds and those recovering from juvenile dermatomyositis. 61
23666925 2013
365
[Unrecognized juvenile dermatomyositis complicated by calcinosis universalis: a case report from Cameroon]. 61
24401174 2013
366
Clinical features and disease course of patients with juvenile dermatomyositis. 61
24164844 2013
367
Juvenile dermatomyositis at a tertiary care hospital: is there any change in the last decade? 61
24164843 2013
368
Disease patterns of juvenile dermatomyositis from Western India. 61
23798628 2013
369
The lung is involved in juvenile dermatomyositis. 61
23281200 2013
370
[Generalized edema as a form of presentation of juvenile dermatomyositis]. 61
23477928 2013
371
Juvenile dermatomyositis management: moving but in need of a push. 61
24164834 2013
372
Interferon-α induction and detection of anti-ro, anti-la, anti-sm, and anti-rnp autoantibodies by autoantigen microarray analysis in juvenile dermatomyositis. 61
23740815 2013
373
Vaccinations in juvenile chronic inflammatory diseases: an update. 61
23820860 2013
374
Cutaneous calcinosis in juvenile dermatomyositis. 61
23608558 2013
375
Immunogenicity of the bivalent human papillomavirus vaccine in adolescents with juvenile systemic lupus erythematosus or juvenile dermatomyositis. 61
23997002 2013
376
An update on inflammatory myositis in children. 61
23912317 2013
377
Childhood dermatomyositis recurring in adulthood half a century later. 61
24000211 2013
378
Myeloid related protein induces muscle derived inflammatory mediators in juvenile dermatomyositis. 61
24286299 2013
379
Brief report: ultraviolet radiation exposure is associated with clinical and autoantibody phenotypes in juvenile myositis. 61
23658122 2013
380
The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies. 61
23877355 2013
381
Dyslipidaemia in juvenile dermatomyositis: the role of disease activity. 61
23557696 2013
382
Longitudinal peripheral blood lymphocyte subsets correlate with decreased disease activity in juvenile dermatomyositis. 61
23678152 2013
383
Severe vocal cord dysfunction: an unusual complication of juvenile dermatomyositis. 61
23637383 2013
384
The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis. 61
22736096 2013
385
[Myositis-specific autoantibodies]. 61
23568993 2013
386
Adult and juvenile dermatomyositis: are the distinct clinical features explained by our current understanding of serological subgroups and pathogenic mechanisms? 61
23566358 2013
387
Update on the treatment of calcinosis in dermatomyositis. 61
23856799 2013
388
MRI guided wire localization muscle biopsy in a child with juvenile dermatomyositis. 61
23566445 2013
389
Interstitial lung disease as an unusual presenting symptom in juvenile dermatomyositis. 61
22157423 2013
390
Doubly robust estimation, optimally truncated inverse-intensity weighting and increment-based methods for the analysis of irregularly observed longitudinal data. 61
23047604 2013
391
Hyperimmunoglobulin E syndrome with juvenile dermatomyositis and calcinosis. 61
20373123 2013
392
Clinical analysis of 50 children with juvenile dermatomyositis. 61
22526832 2013
393
Chronic nonbacterial osteomyelitis in a child with previous juvenile dermatomyositis. 61
23457403 2013
394
Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. 61
23124935 2013
395
Disease activity measures in paediatric rheumatic diseases. 61
24089617 2013
396
Cardiovascular risk in pediatric-onset rheumatological diseases. 61
23731870 2013
397
Juvenile dermatomyositis. 61
23622367 2013
398
Idiopathic inflammatory myopathies: current trends in pathogenesis, clinical features, and up-to-date treatment recommendations. 61
23274022 2013
399
The clinical phenotypes of the juvenile idiopathic inflammatory myopathies. 61
23263716 2013
400
Juvenile dermatomyositis in pregnancy. 61
23662227 2013
401
Therapy of calcinosis universalis complicating adult dermatomyositis. 61
24131911 2013
402
Intravenous immunoglobulin-induced hemolytic anemia in a patient with juvenile dermatomyositis. 61
23377338 2013
403
Calcinosis universalis complicating juvenile dermatomyositis: improvement after intravenous immunoglobulin therapy. 61
22999904 2013
404
Near-infrared spectroscopy during exercise and recovery in children with juvenile dermatomyositis. 61
23042630 2013
405
Accumulation of mature B cells in the inflamed muscle tissue of a patient with anti-155/140 antibody-positive juvenile dermatomyositis. 61
22454192 2013
406
Current treatment strategies: collagen vascular diseases in children. 61
23248363 2012
407
Increased expression of vascular cell adhesion molecule 1 in muscle biopsy samples from juvenile dermatomyositis patients with short duration of untreated disease is regulated by miR-126. 61
22740338 2012
408
Comparison of children with onset of juvenile dermatomyositis symptoms before or after their fifth birthday in a UK and Ireland juvenile dermatomyositis cohort study. 61
22674907 2012
409
Paediatric rheumatic disease: Defining clinically inactive disease in juvenile dermatomyositis. 61
23027027 2012
410
A severe case of universal calcinosis with juvenile dermatomyositis. 61
23075660 2012
411
Juvenile systemic lupus erythematosus and dermatomyositis associated with urticarial vasculitis syndrome: a unique presentation. 61
20429007 2012
412
Nailfold capillaroscopy in children and adolescents with rheumatic diseases. 61
23090372 2012
413
Anti-SAE antibodies in autoimmune myositis: identification by unlabelled protein immunoprecipitation in an Italian patient cohort. 61
22884621 2012
414
Spontaneous pneumomediastinum: a rare complication of juvenile dermatomyositis. 61
23083050 2012
415
Methylation alterations of WT1 and homeobox genes in inflamed muscle biopsy samples from patients with untreated juvenile dermatomyositis suggest self-renewal capacity. 61
22674142 2012
416
Sketched x-rays: Calcinosis universalis. 61
22847171 2012
417
Cyclosporine-induced haemolytic anaemia in a child with juvenile dermatomyositis. 61
22977058 2012
418
Inverse Gottron's papules: an unusual cutaneous manifestation of juvenile dermatomyositis. 61
22211376 2012
419
Nephrotic syndrome and juvenile dermatomyositis. 61
21792647 2012
420
Is juvenile dermatomyositis a different disease in children up to three years of age at onset than in children above three years at onset? A retrospective review of 23 years of a single center's experience. 61
22995763 2012
421
Exercise training in juvenile dermatomyositis. 61
22505288 2012
422
Skeletal muscle major histocompatibility complex class I and II expression differences in adult and juvenile dermatomyositis. 61
22948454 2012
423
[The recommendations on diagnosis and management of children with juvenile dermatomyositis]. 61
23158741 2012
424
[Interpretation of "the recommendations on diagnosis and management of children with juvenile dermatomyositis"]. 61
23158743 2012
425
High frequency of calcinosis in juvenile dermatomyositis: a risk factor study. 61
22885422 2012
426
Influenza A H1N1/2009 vaccine in juvenile dermatomyositis: reduced immunogenicity in patients under immunosuppressive therapy. 61
22931582 2012
427
[Plasmapheresis for macrophage activation syndrome and multiorgan failure as first presentation of juvenile dermatomyositis]. 61
22342516 2012
428
Oral chronic hyperplastic candidiasis associated with juvenile dermatomyositis. 61
22930057 2012
429
Quality of life in adults with juvenile-onset dermatomyositis: a case-control study. 61
22328537 2012
430
Design of the muscles in motion study: a randomized controlled trial to evaluate the efficacy and feasibility of an individually tailored home-based exercise training program for children and adolescents with juvenile dermatomyositis. 61
22721424 2012
431
Exercise in inflammatory myopathies, including inclusion body myositis. 61
22467380 2012
432
Maternal microchimerism in muscle biopsies from children with juvenile dermatomyositis. 61
22271755 2012
433
High frequency of osteoporosis and fractures in women with dermatomyositis/polymyositis. 61
21327426 2012
434
[Clinical characteristics of juvenile dermatomyositis complicated with interstitial lung disease]. 61
22931947 2012
435
[Juvenile dermatomyositis presenting with anasarca: case report and literature review]. 61
22883046 2012
436
A fatal presentation of dermatomyositis with facial swelling. 61
22376996 2012
437
Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy. 61
22258483 2012
438
Mycophenolate mofetil therapy for juvenile dermatomyositis with immune thrombocytopenic purpura. 61
21710356 2012
439
Increased muscle expression of interleukin-17 in Duchenne muscular dystrophy. 61
22496194 2012
440
Recurrent ventricular tachycardia in a child with juvenile dermatomyositis - an unusual association. 61
22462430 2012
441
Consensus treatments for moderate juvenile dermatomyositis: beyond the first two months. Results of the second Childhood Arthritis and Rheumatology Research Alliance consensus conference. 61
22076847 2012
442
Lung involvement in rheumatologic diseases in children. 61
21684670 2012
443
Abatacept and sodium thiosulfate for treatment of recalcitrant juvenile dermatomyositis complicated by ulceration and calcinosis. 61
22244459 2012
444
Thrombotic microangiopathy and Purtscher-like retinopathy as a rare presentation of juvenile dermatomyositis. 61
22311994 2012
445
Soft tissue and subcutaneous calcification in connective tissue diseases. 61
22227955 2012
446
Exercise as a therapeutic modality in patients with idiopathic inflammatory myopathies. 61
22189517 2012
447
Mycophenolate mofetil in juvenile dermatomyositis: a case series. 61
21152922 2012
448
Long-term outcome in patients with juvenile dermatomyositis: a cross-sectional follow-up study. 61
22044089 2012
449
Disease activity, proteinuria, and vitamin D status in children with systemic lupus erythematosus and juvenile dermatomyositis. 61
21924736 2012
450
Juvenile dermatomyositis: new insights and new treatment strategies. 61
22870494 2012
451
Glucocorticoid: major factor for reduced immunogenicity of 2009 influenza A (H1N1) vaccine in patients with juvenile autoimmune rheumatic disease. 61
22089462 2012
452
Incident vertebral fractures among children with rheumatic disorders 12 months after glucocorticoid initiation: a national observational study. 61
22213727 2012
453
[Some aspects of idiopathic myopathies of childhood]. 61
23547388 2012
454
Organ-specific autoantibodies and autoimmune diseases in juvenile systemic lupus erythematosus and juvenile dermatomyositis patients. 61
22261392 2012
455
[Juvenile dermatomyositis]. 61
23745459 2012
456
Dramatic heliotrope dermatitis and uncommon pulmonary involvement in juvenile dermatomyositis. 61
22665709 2012
457
Efficacy of intravenous Ig therapy in juvenile dermatomyositis. 61
21978999 2011
458
Assessment of active inflammation in juvenile dermatomyositis: a novel magnetic resonance imaging-based scoring system. 61
21972421 2011
459
Autoimmune neuromuscular disorders in childhood. 61
21912840 2011
460
The co-existence of vulvar lichen sclerosus, ulcerated calcinosis cutis, and dermatomyositis: coincidence or immunological mechanism? 61
22346282 2011
461
Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI). 61
22588740 2011
462
Ovarian teratoma mimicking features of juvenile dermatomyositis in a child. 61
21969283 2011
463
Clinical status and cardiovascular risk profile of adults with a history of juvenile dermatomyositis. 61
21784434 2011
464
Picture of the month--quiz case. Juvenile dermatomyositis. 61
22065185 2011
465
Sleep and fatigue and the relationship to pain, disease activity and quality of life in juvenile idiopathic arthritis and juvenile dermatomyositis. 61
21873265 2011
466
Therapeutic approaches in the treatment of juvenile dermatomyositis in patients with recent-onset disease and in those experiencing disease flare: an international multicenter PRINTO study. 61
21647864 2011
467
Juvenile dermatomyositis presenting as an acquired inflammatory Blaschko-linear dermatosis. 61
21920239 2011
468
[The changed lives of children and adolescents with juvenile dermatomyositis - 3 case studies]. 61
22029140 2011
469
Glucocorticoids in paediatric rheumatology. 61
22018202 2011
470
Results of the German ESPED-recording of new patients with juvenile dermatomyositis (JDM). 61
21509712 2011
471
Therapeutic effects of exercise training in patients with pediatric rheumatic diseases. 61
21953000 2011
472
Juvenile systemic lupus erythematosus: A diagnostic dilemma. 61
22346244 2011
473
Idiopathic inflammatory myopathies in childhood: a brief review of 27 cases. 61
21723454 2011
474
Juvenile dermatomyositis: immunopathogenesis, role of myositis-specific autoantibodies, and review of rituximab use. 61
21793879 2011
475
Can maternal microchimeric cells influence the fetal response toward self antigens? 61
22163064 2011
476
[Dermatomyositis: assessment and follow-up of 20 patients]. 61
21411047 2011
477
Juvenile dermatomyositis. 61
21777536 2011
478
Safety and efficacy of rituximab in severe juvenile dermatomyositis: results from 9 patients from the French Autoimmunity and Rituximab registry. 61
21677003 2011
479
Double trouble: therapeutic challenges in patients with both juvenile dermatomyositis and psoriasis. 61
21422326 2011
480
[Effective cyclophosphamide pulse therapy for an young infant with severe dermatomyositis]. 61
21800697 2011
481
Juvenile dermatomyositis: correlation of MRI at presentation with clinical outcome. 61
21700978 2011
482
Critical care of the pediatric patient with rheumatic disease. 61
21467937 2011
483
Type I interferon and Toll-like receptor expression characterizes inflammatory myopathies. 61
21670437 2011
484
Juvenile dermatomyositis. 61
21312074 2011
485
Adult outcomes of childhood-onset rheumatic diseases. 61
21487383 2011
486
Criteria to define response to therapy in paediatric rheumatic diseases. 61
21103985 2011
487
Familial aggregation of autoimmune disease in juvenile dermatomyositis. 61
21502224 2011
488
Nailfold capillary density is importantly associated over time with muscle and skin disease activity in juvenile dermatomyositis. 61
21156669 2011
489
Actuality of juvenile dermatomyositis. 61
21276742 2011
490
Late onset calcification following juvenile dermatomyositis: response with weekly alendronate. 61
21772617 2011
491
Cardiac dysfunction in juvenile dermatomyositis: a case-control study. 61
21216816 2011
492
Anti-CADM-140 antibody-positive juvenile dermatomyositis with rapidly progressive interstitial lung disease and cardiac involvement. 61
21532064 2011
493
Anti-melanoma differentiation-associated gene 5 antibody is a diagnostic and predictive marker for interstitial lung diseases associated with juvenile dermatomyositis. 61
21232756 2011
494
Extensive calcinosis in juvenile dermatomyositis. 61
21841739 2011
495
Serum neopterin levels as a diagnostic marker of hemophagocytic lymphohistiocytosis syndrome. 61
21270283 2011
496
Penile and scrotum swelling in juvenile dermatomyositis. 61
21841738 2011
497
Cutaneous manifestations of connective tissue disease. 61
21815443 2011
498
Immunogenicity of influenza vaccine in children with pediatric rheumatic diseases receiving immunosuppressive agents. 61
20861757 2011
499
Bisphosphonate use in conditions other than osteoporosis. 61
20946575 2011
500
Autoantibody to PL-12 (Anti-Alanyl-tRNA synthetase) in an African American girl with juvenile dermatomyositis and resolution of interstitial lung disease. 61
21285181 2011
501
Blood relatives of follicular helper T cells. 61
21272784 2011
502
A case of juvenile dermatomyositis with severe calcinosis and successful treatment with prednisone and diltiazem. 61
21182506 2011
503
Pulmonary outcome in juvenile dermatomyositis: a case-control study. 61
20805295 2011
504
Type I interferon pathway in adult and juvenile dermatomyositis. 61
22192711 2011
505
Comparison of clinical features and drug therapies among European and Latin American patients with juvenile dermatomyositis. 61
21345298 2011
506
Juvenile dermatomyositis: a case study. 61
21147406 2011
507
Oral manifestations as important symptoms for juvenile dermatomyositis early diagnosis: a case report. 61
20659183 2011
508
Human blood CXCR5(+)CD4(+) T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion. 61
21215658 2011
509
Plasma proteomic profiles from disease-discordant monozygotic twins suggest that molecular pathways are shared in multiple systemic autoimmune diseases. 61
22044644 2011
510
A national registry for juvenile dermatomyositis and other paediatric idiopathic inflammatory myopathies: 10 years' experience; the Juvenile Dermatomyositis National (UK and Ireland) Cohort Biomarker Study and Repository for Idiopathic Inflammatory Myopathies. 61
20823094 2011
511
A case of juvenile dermatomyositis manifesting inflammatory epidermal nevus-like skin lesions: unrecognized cutaneous manifestation of blaschkitis? 61
20962570 2010
512
Juvenile dermatomyositis with tongue calcinosis and poor growth. 61
21030377 2010
513
Benign pneumatosis intestinalis in a patient with juvenile dermatomyositis. 61
21041270 2010
514
Responsiveness to exercise training in juvenile dermatomyositis: a twin case study. 61
21106107 2010
515
The Paediatric Rheumatology International Trials Organisation provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis. 61
20583105 2010
516
Approach to a patient with connective tissue disease. 61
20924723 2010
517
MMF for juvenile derMatoMyositis. 61
20925150 2010
518
Mycophenolate mofetil: a possible therapeutic agent for children with juvenile dermatomyositis. 61
20521307 2010
519
Gingival capillary changes and oral motor weakness in juvenile dermatomyositis. 61
20591830 2010
520
Gene-gene-sex interaction in cytokine gene polymorphisms revealed by serum interferon alpha phenotype in juvenile dermatomyositis. 61
20605164 2010
521
The use of methotrexate in children with rheumatic diseases. 61
21044445 2010
522</